

Overcoming Limitations in Decarboxylative Arylation via Ag-Ni Electrocatalysis

Maximilian D. Palkowitz[‡], Gabriele Laudadio[‡], Simon Kolb[‡], Jin Choi[‡], Martins S. Oderinde[‡], Tamara El-Hayek Ewing[‡], Philippe N. Bolduc[∇], TeYu Chen[∇], Hao Zhang[‡], Peter T. W. Cheng[‡], Benxiang Zhang[‡], Michael Mandler[‡], Vanna D. Blaszczak[∇], Jeremy M. Richter[‡], Michael R. Collins[⊕], Ryan L. Schioldager[⊕], Martin Bravo[⊕], T. G. Murali Dhar[‡], Benjamin Vokits[‡], Yeheng Zhu[‡], Pierre-Georges Echeverria[∩], Michael A. Poss[‡], Scott A. Shaw[‡], Sebastian Clementson[∠], Nadia Nasser Petersen[∠], Pavel K. Mykhailiuk[∅] and Phil S. Baran^{‡*}

[‡]Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States

[‡]Bristol Myers Squibb Research and Development, PO Box 4000, Princeton, New Jersey, 08534, United States

[∇]Biogen Inc., 225 Binney Street, Cambridge, MA 02142, United States

[⊕]Pfizer Pharmaceuticals, Oncology Medicinal Chemistry Department, 10770 Science Center Drive, San Diego, CA 92121, United States

[∩]Minakem Recherche, 145 Chemin des Lilas, Beuvry-La-Forêt 59310, France

[∠]Research and Early Development, LEO Pharma A/S, 2750 Ballerup, Denmark

[∅]Enamine Ltd; Chervonotkatska 60, 02094 Kyiv, Ukraine

Correspondence to *pbaran@scripps.edu

Supporting Information

Table of Contents

GENERAL EXPERIMENTAL INFORMATION	7
GENERAL PROCEDURE 1: SYNTHESIS OF NHPI REDOX ACTIVE ESTERS	8
TABLE S1 – KNOWN NHPI REDOX ACTIVE ESTERS	9
GENERAL SUPPORTING INFORMATION FOR NHPI REDOX ACTIVE ESTERS	10
COMPOUND S5	10
COMPOUND S6	11
COMPOUND S10	12
COMPOUND S12	13
COMPOUND S22	14
COMPOUND 39	15
COMPOUND S27	16
COMPOUND S30	17
COMPOUND S31	18
COMPOUND S32	19
COMPOUND S33	20
COMPOUND 52	21
SYNTHESIS OF OTHER STARTING MATERIALS	22
COMPOUND 56	22
GENERAL PROCEDURE 2: AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION (0.4 MMOL SCALE)	23
VISUAL GUIDE FOR GENERAL PROCEDURE 2	24
GENERAL PROCEDURE 3: IN SITU AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION (0.4 MMOL SCALE)	29
VISUAL GUIDE	30
GENERAL PROCEDURE 4: AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION (5 MMOL SCALE)	33
VISUAL GUIDE	34
GENERAL PROCEDURE 5: AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION IN RECIRCULATING FLOW (100 MMOL)	36
MAKING THE FLOW CELL COMPONENTS	36
FLOW REACTOR ASSEMBLY	36
RUNNING THE REACTION	37
VISUAL GUIDE FOR RECIRCULATING FLOW SCALE UP	39
PARALLEL SYNTHESIS IN IKA E-HIVE	42
TABLE S2: ARENE SCREEN AGAINST 55 (PERMITTED USE OF LOGO IS CREDITED TO IKA.)	42
TABLE S3: RAE SCREEN AGAINST 56 (PERMITTED USE OF LOGO IS CREDITED TO IKA.)	43
TABLE S4: ISOLATED AMOUNTS OF PRODUCT FROM THE E-HIVE	45
NEGATIVE CONTROL FOR E-HIVE REACTIONS ON PREPARATIVE SCALE	45
VISUAL GUIDE FOR PARALLEL SYNTHESIS IN E-HIVE	46
FAQ'S	48
TROUBLESHOOTING GUIDE	50
ZINC MEDIATED DCC CONTROL	51
ELECTROCHEMICALLY MEDIATED DCC CONTROL	51

REDUCTIVE PHOTOCHEMICAL DCC CONTROL.....	52
OXIDATIVE PHOTOCHEMICAL ACTIVATION DCC CONTROL.....	52
PRIOR ATTEMPTS AT ACCESSING 51.....	53
NEGISHI-DCC	53
ZN-MEDIATED DCC.....	54
REDUCTIVE PHOTOCHEMICAL ACTIVATION	54
OXIDATIVE PHOTOCHEMICAL ACTIVATION.....	55
OPTIMIZATION OF THE AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION	56
TABLE S5: SOLVENT SCREEN	56
TABLE S6: ELECTRODE SCREEN	56
TABLE S7: SILVER LOADING AND F/MOL	57
TABLE S8: ADDITIVE SCREEN	57
TABLE S9: ELECTROCHEMICAL PARAMETERS AND CONCENTRATION	58
TABLE S10: NICKEL SOURCE SCREEN	58
TABLE S11: LIGAND SCREEN	59
TABLE S12: LIGAND STOICHIOMETRY.....	59
TABLE S13: CATALYST LOADING.....	60
TABLE S14: ARENE STOICHIOMETRY	60
TABLE S15: RAE STOICHIOMETRY	61
TABLE S16: CONTROL STUDY (UNDER ARGON).....	61
TABLE S17: CONTROL STUDY (OPEN FLASK).....	62
TABLE S18: STATE OF THE ART COMPARISONS WITH EXISTING METHODS TO ACCESS 38.....	63
TABLE S19: COMPARISON OF SUBSTRATES WITH AND WITHOUT SILVER	64
PROCEDURES AND CHARACTERIZATION OF AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION PRODUCTS.....	65
COMPOUND 1.....	65
COMPOUND 4.....	66
COMPOUND 5.....	67
COMPOUND 6.....	67
COMPOUND 7.....	68
COMPOUND 8.....	69
COMPOUND 9.....	70
COMPOUND 10.....	71
COMPOUND 11.....	71
COMPOUND 12.....	72
COMPOUND 13.....	73
COMPOUND 14.....	74
COMPOUND 15.....	74
COMPOUND 16.....	75
COMPOUND 17.....	75
COMPOUND 18.....	76
COMPOUND 19.....	77
COMPOUND 20.....	78
COMPOUND 21.....	79
COMPOUND 22.....	79
COMPOUND 23.....	80
COMPOUND 24.....	81
COMPOUND 25.....	82
COMPOUND 26.....	82

COMPOUND 27.....	83
COMPOUND 28.....	84
COMPOUND 29.....	85
COMPOUND 30.....	85
COMPOUND 31.....	86
COMPOUND 32.....	86
COMPOUND 33.....	87
COMPOUND 34.....	88
COMPOUND 35.....	89
COMPOUND 36.....	90
COMPOUND 37.....	91
COMPOUND 38.....	92
COMPOUND 40.....	93
COMPOUND 44.....	93
COMPOUND 48.....	94
COMPOUND 51.....	94
COMPOUND 81.....	95
COMPOUND 82.....	96
COMPOUND 83.....	97
COMPOUND 84.....	98
COMPOUND 85.....	99
COMPOUND 86.....	100
COMPOUND S34.....	101
COMPOUND S35.....	101
REFERENCES	103
NMR SPECTRA	106
COMPOUND S5 ¹ H-NMR	107
COMPOUND S5 ¹³ C-NMR.....	108
COMPOUND S6 ¹ H-NMR	109
COMPOUND S6 ¹³ C-NMR.....	110
COMPOUND S10 ¹ H-NMR	111
COMPOUND S10 ¹³ C-NMR.....	112
COMPOUND S12 ¹ H-NMR	113
COMPOUND S12 ¹³ C-NMR.....	114
COMPOUND S22 ¹ H-NMR	115
COMPOUND S22 ¹³ C-NMR.....	116
COMPOUND 39 ¹ H-NMR	117
COMPOUND 39 ¹³ C-NMR.....	118
COMPOUND S27 ¹ H-NMR	119
COMPOUND S27 ¹³ C-NMR.....	120
COMPOUND S30 ¹ H-NMR	121
COMPOUND S30 ¹³ C-NMR.....	122
COMPOUND S31 ¹ H-NMR	123
COMPOUND S31 ¹³ C-NMR.....	124
COMPOUND S32 ¹ H-NMR	125
COMPOUND S32 ¹³ C-NMR.....	126
COMPOUND S32 ¹⁹ F-NMR	127
COMPOUND S33 ¹ H-NMR	128
COMPOUND S33 ¹³ C-NMR.....	129
COMPOUND 50 ¹ H-NMR	130
COMPOUND 50 ¹³ C-NMR.....	131

COMPOUND 56 ¹ H-NMR	132
COMPOUND 56 ¹³ C-NMR	133
COMPOUND 1 ¹ H-NMR	134
COMPOUND 1 ¹³ C-NMR	135
COMPOUND 4 ¹ H-NMR	136
COMPOUND 4 ¹³ C-NMR	137
COMPOUND 7 ¹ H-NMR	138
COMPOUND 7 ¹³ C-NMR	139
COMPOUND 8 ¹ H-NMR	140
COMPOUND 8 ¹³ C-NMR	141
COMPOUND 9 ¹ H-NMR	142
COMPOUND 9 ¹³ C-NMR	143
COMPOUND 10 ¹ H-NMR	144
COMPOUND 10 ¹³ C-NMR	145
COMPOUND 12 ¹ H-NMR	146
COMPOUND 12 ¹³ C-NMR	147
COMPOUND 13 ¹ H-NMR	148
COMPOUND 13 ¹³ C-NMR	149
COMPOUND 13 ¹⁹ F-NMR.....	150
COMPOUND 14 ¹ H-NMR	151
COMPOUND 14 ¹³ C-NMR	152
COMPOUND 16 ¹ H-NMR	153
COMPOUND 16 ¹³ C-NMR	154
COMPOUND 17 ¹ H-NMR	155
COMPOUND 17 ¹³ C-NMR	156
COMPOUND 18 ¹ H-NMR	157
COMPOUND 18 ¹³ C-NMR	158
COMPOUND 19 ¹ H-NMR	159
COMPOUND 19 ¹³ C-NMR	160
COMPOUND 20 ¹ H-NMR	161
COMPOUND 20 ¹³ C-NMR	162
COMPOUND 21 ¹ H-NMR	163
COMPOUND 21 ¹³ C-NMR	164
COMPOUND 23 ¹ H-NMR	165
COMPOUND 23 ¹³ C-NMR	166
COMPOUND 24 ¹ H-NMR	167
COMPOUND 24 ¹³ C-NMR	168
COMPOUND 25 ¹ H-NMR	169
COMPOUND 25 ¹³ C-NMR	170
COMPOUND 26 ¹ H-NMR	171
COMPOUND 26 ¹³ C-NMR	172
COMPOUND 27 ¹ H-NMR	173
COMPOUND 27 ¹³ C-NMR	174
COMPOUND 28 ¹ H-NMR	175
COMPOUND 28 ¹³ C-NMR	176
COMPOUND 29 ¹ H-NMR	177
COMPOUND 29 ¹³ C-NMR	178
COMPOUND 31 ¹ H-NMR	179
COMPOUND 31 ¹³ C-NMR	180
COMPOUND 33 ¹ H-NMR	181
COMPOUND 33 ¹³ C-NMR	182
COMPOUND 33 ¹⁹ F-NMR.....	183
COMPOUND 34 ¹ H-NMR	184

COMPOUND 34 ¹³ C-NMR	185
COMPOUND 34 ¹⁹ F-NMR.....	186
COMPOUND 35 ¹ H-NMR	187
COMPOUND 35 ¹³ C-NMR	188
COMPOUND 36 ¹ H-NMR	189
COMPOUND 36 ¹³ C-NMR	190
COMPOUND 37 ¹ H-NMR	191
COMPOUND 37 ¹³ C-NMR	192
COMPOUND 38 ¹ H-NMR	193
COMPOUND 38 ¹³ C-NMR	194
COMPOUND 44 ¹ H-NMR	195
COMPOUND 44 ¹³ C-NMR	196
COMPOUND 51 ¹ H-NMR	197
COMPOUND 51 ¹³ C-NMR	198
COMPOUND 81 ¹ H-NMR	199
COMPOUND 81 ¹³ C-NMR	200
COMPOUND 81 ¹⁹ F-NMR.....	201
COMPOUND 82 ¹ H-NMR	202
COMPOUND 82 ¹³ C-NMR	203
COMPOUND 83 ¹ H-NMR	204
COMPOUND 83 ¹³ C-NMR	205
COMPOUND 84 ¹ H-NMR	206
COMPOUND 84 ¹³ C-NMR	207
COMPOUND 85 ¹ H-NMR	208
COMPOUND 85 ¹³ C-NMR	209
COMPOUND 86 ¹ H-NMR	210
COMPOUND 86 ¹³ C-NMR	211
COMPOUND S34 ¹ H-NMR	212
COMPOUND S34 ¹³ C-NMR	213
COMPOUND S35 ¹ H-NMR	214
COMPOUND S35 ¹³ C-NMR	215
GENERAL EXPERIMENTAL INFORMATION	7
GENERAL PROCEDURE 1: SYNTHESIS OF NHPI REDOX ACTIVE ESTERS	8
TABLE S1 – KNOWN NHPI REDOX ACTIVE ESTERS.....	9
GENERAL SUPPORTING INFORMATION FOR NHPI REDOX ACTIVE ESTERS	10
COMPOUND S5.....	10
COMPOUND S6.....	11
COMPOUND S10.....	12
COMPOUND S12.....	13
COMPOUND S22.....	14
COMPOUND 39.....	15
COMPOUND S27.....	16
COMPOUND S30.....	17
COMPOUND S31.....	18
COMPOUND S32.....	19
COMPOUND S33.....	20
COMPOUND 52.....	21
SYNTHESIS OF OTHER STARTING MATERIALS	22
COMPOUND 56.....	22

GENERAL PROCEDURE 2: AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION (0.4 MMOL SCALE)	23
VISUAL GUIDE FOR GENERAL PROCEDURE 2.....	24
GENERAL PROCEDURE 3: IN SITU AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION (0.4 MMOL SCALE)	29
VISUAL GUIDE.....	30
GENERAL PROCEDURE 4: AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION (5 MMOL SCALE)	33
VISUAL GUIDE.....	34
GENERAL PROCEDURE 5: AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION IN RECIRCULATING FLOW (100 MMOL)	36
MAKING THE FLOW CELL COMPONENTS.....	36
FLOW REACTOR ASSEMBLY.....	36
RUNNING THE REACTION.....	37
VISUAL GUIDE FOR RECIRCULATING FLOW SCALE UP.....	39
PARALLEL SYNTHESIS IN IKA E-HIVE	42
TABLE S2: ARENE SCREEN AGAINST 55 (PERMITTED USE OF LOGO IS CREDITED TO IKA.).....	42
TABLE S3: RAE SCREEN AGAINST 56 (PERMITTED USE OF LOGO IS CREDITED TO IKA.).....	42
TABLE S4: ISOLATED AMOUNTS OF PRODUCT FROM THE E-HIVE.....	45
NEGATIVE CONTROL FOR E-HIVE REACTIONS ON PREPARATIVE SCALE.....	45
VISUAL GUIDE FOR PARALLEL SYNTHESIS IN E-HIVE.....	46
FAQ'S	48
TROUBLESHOOTING GUIDE	50
ZINC MEDIATED DCC CONTROL	51
ELECTROCHEMICALLY MEDIATED DCC CONTROL	51
REDUCTIVE PHOTOCHEMICAL DCC CONTROL	52
OXIDATIVE PHOTOCHEMICAL ACTIVATION DCC CONTROL	52
PRIOR ATTEMPTS AT ACCESSING 51	53
NEGISHI-DCC.....	53
Zn-MEDIATED DCC.....	54
REDUCTIVE PHOTOCHEMICAL ACTIVATION.....	54
OXIDATIVE PHOTOCHEMICAL ACTIVATION.....	55
OPTIMIZATION OF THE AG-NI ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION	56
TABLE S5: SOLVENT SCREEN.....	56
TABLE S6: ELECTRODE SCREEN.....	56
TABLE S7: SILVER LOADING AND F/MOL.....	57
TABLE S8: ADDITIVE SCREEN.....	57
TABLE S9: ELECTROCHEMICAL PARAMETERS AND CONCENTRATION.....	58
TABLE S10: NICKEL SOURCE SCREEN.....	58
TABLE S11: LIGAND SCREEN.....	59
TABLE S12: LIGAND STOICHIOMETRY.....	59
TABLE S13: CATALYST LOADING.....	60
TABLE S14: ARENE STOICHIOMETRY.....	60
TABLE S15: RAE STOICHIOMETRY.....	61
TABLE S16: CONTROL STUDY (UNDER ARGON).....	61
TABLE S17: CONTROL STUDY (OPEN FLASK).....	62

TABLE S18: STATE OF THE ART COMPARISONS WITH EXISTING METHODS TO ACCESS 38.....	63
---	----

TABLE S19: COMPARISON OF SUBSTRATES WITH AND WITHOUT SILVER	64
---	----

PROCEDURES AND CHARACTERIZATION OF Ag-Ni ELECTROCATALYTIC DECARBOXYLATIVE ARYLATION

PRODUCTS.....	65
----------------------	-----------

COMPOUND 1.....	65
-----------------	----

COMPOUND 4.....	66
-----------------	----

COMPOUND 5.....	67
-----------------	----

COMPOUND 6.....	67
-----------------	----

COMPOUND 7.....	68
-----------------	----

COMPOUND 8.....	69
-----------------	----

COMPOUND 9.....	70
-----------------	----

COMPOUND 10.....	71
------------------	----

COMPOUND 11.....	71
------------------	----

COMPOUND 12.....	72
------------------	----

COMPOUND 13.....	73
------------------	----

COMPOUND 14.....	74
------------------	----

COMPOUND 15.....	74
------------------	----

COMPOUND 16.....	75
------------------	----

COMPOUND 17.....	75
------------------	----

COMPOUND 18.....	76
------------------	----

COMPOUND 19.....	77
------------------	----

COMPOUND 20.....	78
------------------	----

COMPOUND 21.....	79
------------------	----

COMPOUND 22.....	79
------------------	----

COMPOUND 23.....	80
------------------	----

COMPOUND 24.....	81
------------------	----

COMPOUND 25.....	82
------------------	----

COMPOUND 26.....	82
------------------	----

COMPOUND 27.....	83
------------------	----

COMPOUND 28.....	84
------------------	----

COMPOUND 29.....	85
------------------	----

COMPOUND 30.....	85
------------------	----

COMPOUND 31.....	86
------------------	----

COMPOUND 32.....	86
------------------	----

COMPOUND 33.....	87
------------------	----

COMPOUND 34.....	88
------------------	----

COMPOUND 35.....	89
------------------	----

COMPOUND 36.....	90
------------------	----

COMPOUND 37.....	91
------------------	----

COMPOUND 38.....	92
------------------	----

COMPOUND 40.....	93
------------------	----

COMPOUND 44.....	93
------------------	----

COMPOUND 48.....	94
------------------	----

COMPOUND 51.....	94
------------------	----

COMPOUND 81.....	95
------------------	----

COMPOUND 82.....	96
------------------	----

COMPOUND 83.....	97
------------------	----

COMPOUND 84.....	98
------------------	----

COMPOUND 85.....	99
------------------	----

COMPOUND 86.....	100
------------------	-----

COMPOUND S34.....	101
-------------------	-----

COMPOUND S35.....	101
-------------------	-----

REFERENCES	103
NMR SPECTRA	106
COMPOUND S5 1H-NMR	107
COMPOUND S5 13C-NMR	108
COMPOUND S6 1H-NMR	109
COMPOUND S6 13C-NMR	110
COMPOUND S10 1H-NMR	111
COMPOUND S10 13C-NMR	112
COMPOUND S12 1H-NMR	113
COMPOUND S12 13C-NMR	114
COMPOUND S22 1H-NMR	115
COMPOUND S22 13C-NMR	116
COMPOUND 39 1H-NMR	117
COMPOUND 39 13C-NMR	118
COMPOUND S27 1H-NMR	119
COMPOUND S27 13C-NMR	120
COMPOUND S30 1H-NMR	121
COMPOUND S30 13C-NMR	122
COMPOUND S31 1H-NMR	123
COMPOUND S31 13C-NMR	124
COMPOUND S32 1H-NMR	125
COMPOUND S32 13C-NMR	126
COMPOUND S32 19F-NMR	127
COMPOUND S33 1H-NMR	128
COMPOUND S33 13C-NMR	129
COMPOUND 50 1H-NMR	130
COMPOUND 50 13C-NMR	131
COMPOUND 56 1H-NMR	132
COMPOUND 56 13C-NMR	133
COMPOUND 1 1H-NMR	134
COMPOUND 1 13C-NMR	135
COMPOUND 4 1H-NMR	136
COMPOUND 4 13C-NMR	137
COMPOUND 7 1H-NMR	138
COMPOUND 7 13C-NMR	139
COMPOUND 8 1H-NMR	140
COMPOUND 8 13C-NMR	141
COMPOUND 9 1H-NMR	142
COMPOUND 9 13C-NMR	143
COMPOUND 10 1H-NMR	144
COMPOUND 10 13C-NMR	145
COMPOUND 12 1H-NMR	146
COMPOUND 12 13C-NMR	147
COMPOUND 13 1H-NMR	148
COMPOUND 13 13C-NMR	149
COMPOUND 13 19F-NMR	150
COMPOUND 14 1H-NMR	151
COMPOUND 14 13C-NMR	152
COMPOUND 16 1H-NMR	153
COMPOUND 16 13C-NMR	154
COMPOUND 17 1H-NMR	155
COMPOUND 17 13C-NMR	156


COMPOUND 18 1H-NMR	157
COMPOUND 18 13C-NMR	158
COMPOUND 19 1H-NMR	159
COMPOUND 19 13C-NMR	160
COMPOUND 20 1H-NMR	161
COMPOUND 20 13C-NMR	162
COMPOUND 21 1H-NMR	163
COMPOUND 21 13C-NMR	164
COMPOUND 23 1H-NMR	165
COMPOUND 23 13C-NMR	166
COMPOUND 24 1H-NMR	167
COMPOUND 24 13C-NMR	168
COMPOUND 25 1H-NMR	169
COMPOUND 25 13C-NMR	170
COMPOUND 26 1H-NMR	171
COMPOUND 26 13C-NMR	172
COMPOUND 27 1H-NMR	173
COMPOUND 27 13C-NMR	174
COMPOUND 28 1H-NMR	175
COMPOUND 28 13C-NMR	176
COMPOUND 29 1H-NMR	177
COMPOUND 29 13C-NMR	178
COMPOUND 31 1H-NMR	179
COMPOUND 31 13C-NMR	180
COMPOUND 33 1H-NMR	181
COMPOUND 33 13C-NMR	182
COMPOUND 33 19F-NMR	183
COMPOUND 34 1H-NMR	184
COMPOUND 34 13C-NMR	185
COMPOUND 34 19F-NMR	186
COMPOUND 35 1H-NMR	187
COMPOUND 35 13C-NMR	188
COMPOUND 36 1H-NMR	189
COMPOUND 36 13C-NMR	190
COMPOUND 37 1H-NMR	191
COMPOUND 37 13C-NMR	192
COMPOUND 38 1H-NMR	193
COMPOUND 38 13C-NMR	194
COMPOUND 44 1H-NMR	195
COMPOUND 44 13C-NMR	196
COMPOUND 51 1H-NMR	197
COMPOUND 51 13C-NMR	198
COMPOUND 81 1H-NMR	199
COMPOUND 81 13C-NMR	200
COMPOUND 81 19F-NMR	201
COMPOUND 82 1H-NMR	202
COMPOUND 82 13C-NMR	203
COMPOUND 83 1H-NMR	204
COMPOUND 83 13C-NMR	205
COMPOUND 84 1H-NMR	206
COMPOUND 84 13C-NMR	207
COMPOUND 85 1H-NMR	208
COMPOUND 85 13C-NMR	209

COMPOUND 86 1H-NMR.....	210
COMPOUND 86 13C-NMR.....	211
COMPOUND S34 1H-NMR.....	212
COMPOUND S34 13C-NMR.....	213
COMPOUND S35 1H-NMR.....	214
COMPOUND S35 13C-NMR.....	215

General Experimental Information

All reactions were carried out under an inert argon atmosphere with dry solvents under anhydrous conditions unless otherwise stated. All electrochemical experiments were conducted with commercially available ElectraSyn 2.0 and standard equipment unless otherwise stated. The RVC electrodes were purchased from commercial RVC block (purchased from ULTRAMET, 100 ppi, 14.40" x 13.86" x 8"). Optical rotations were recorded using an Anton Paar MCP100 polarimeter. Reagents were either purchased at the highest commercial quality and used without further purification, unless otherwise stated or donated by our industrial collaborators. Yields refer to chromatographically and spectroscopically (^1H NMR or LCMS) homogeneous material, unless otherwise stated. Reactions were monitored by thin layer chromatography (TLC) carried out on 0.25 mm E. Merck silica plates (60F254), using UV light as the visualizing agent and/or p-anisaldehyde, I_2 , ninhydrin, KMnO_4 , dragendorff, DNP and heat as a developing agent. Flash silica gel chromatography was performed using E. Merck silica gel (60, particle size 0.043 – 0.063 mm). NMR spectra were recorded on Bruker DRX600, DRX-500 and AMX-400 instruments and were calibrated using residual undeuterated solvents as an internal reference (chloroform-d: ^1H NMR δ = 7.26 ppm, ^{13}C NMR δ = 77.16 ppm, dimethyl sulfoxide-d₆: ^1H NMR δ = 2.50 ppm, ^{13}C NMR δ = 39.52 ppm, methanol-d₄ ^1H NMR δ = 3.31 ppm, ^{13}C NMR δ = 49.00 ppm). The following abbreviations are used to explain NMR peak multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. High-resolution mass spectra (HRMS) were recorded on an Agilent LC/MSD TOF mass spectrometer by electrospray ionization time-of-flight (ESI-TOF) reflection experiments.

General Procedure 1: Synthesis of NHPI Redox Active Esters




To a stirring solution of carboxylic acid (1.0 equiv.), *N*-hydroxyphthalimide (1.0 equiv.), and 4-dimethylaminopyridine (0.1 equiv.) in anhydrous DCM (0.3 M), DIC (1.1 equiv.) was added via syringe. The reaction mixture was vigorously stirred until complete (monitored by TLC, 0.5 h – 2 h). Upon completion, the mixture was concentrated and was directly purified via silica gel column chromatography to afford the activated ester.

Redox-active esters shown below **2**,¹ **S1**,² **S2**,³ **S3**,⁴ **S4**,¹ **43**,⁵ **S7**,⁶ **S8**, **S18**,⁷ **S9**, **S11**,⁸ **41**,⁹ **S13**,¹⁰ **S14**,¹¹ **S15**,¹² **S16**,¹³ **S18**,¹⁴ **S19**,¹⁵ **S20**,¹⁶ **S21**, **S23**,¹⁷ **S24**, **S28**,¹⁸ **S25**, **45**,¹⁹ **S26**,²⁰ **S29**,²¹ **S34**,²² **S35**,²³ **S36**,²⁴ **S37**,²⁵ **S38**,²⁶ and **48**²⁷ have previously been reported in the literature. Please see these references for characterization. For newly reported redox active esters, HRMS failed to detect the target mass due to instability of the NHPI ester motif.


Table S1 – Known NHPI Redox Active Esters

Known NHPI-Redox Active Esters



General Supporting Information for NHPI Redox Active Esters

Compound S5



Following the General Procedure 1 with N^{α} -(((9*H*-fluoren-9-yl)methoxy)carbonyl)- N^{ϵ} -trityl-L-histidine (12.4 g, 20 mmol), *N*-hydroxyphthalimide (4.08 g, 25 mmol), DMAP (244 mg, 2 mmol) and DIC (3.4 mL, 22 mmol) in DCM (200 mL) at rt for 2 h afforded 12.6 g (88%) of the title compound after purification by column chromatography (hexanes to 1:1 hexanes/ethyl acetate).


Physical State: Yellow solid

^1H NMR (600 MHz, CDCl_3): δ 7.85 – 7.76 (m, 3H), 7.73 (d, $J = 7.7$ Hz, 3H), 7.65 – 7.57 (m, 3H), 7.49 (s, 1H), 7.40 – 7.30 (m, 4H), 7.28 (d, $J = 7.2$ Hz, 4H), 7.25 (d, $J = 6.5$ Hz, 4H), 7.09 (d, $J = 7.6$ Hz, 7H), 6.96 (s, 1H), 5.04 (q, $J = 6.1$ Hz, 1H), 4.40 – 4.12 (m, 3H), 3.35 (qd, $J = 14.9, 5.7$ Hz, 2H).

^{13}C NMR (151 MHz, CDCl_3): δ 168.3, 165.3, 161.4, 156.1, 144.1, 144.0, 142.1, 141.3, 138.7, 134.9, 134.8, 133.9, 129.9, 129.8, 129.6, 129.0, 128.6, 128.4, 128.3, 128.2, 127.7, 127.2, 127.2, 125.6, 125.5, 124.1, 123.2, 121.2, 119.9, 75.9, 67.6, 53.2, 47.2, 29.9.

TLC: $R_f = 0.31$ (1:1 hexanes/ethyl acetate)

Compound S6



Following the General Procedure 1 with 3-(3,4-dimethoxyphenyl)propanoic acid (2.0 g, 9.5 mmol), *N*-hydroxyphthalimide (1.55 g, 9.5 mmol), DMAP (116 mg, 0.95 mmol) and DIC (1.64 mL, 10.5 mmol) in DCM (30 mL) at rt for 2 h afforded 1.82 g (54%) of the title compound after purification by column chromatography (gradient elution, hexanes to 4:1 hexanes/ethyl acetate).


Physical State: Yellow solid

¹H NMR (600 MHz, CDCl₃): δ 7.89 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.79 (dd, *J* = 5.5, 3.1 Hz, 2H), 6.85 – 6.77 (m, 3H), 3.90 (s, 3H), 3.87 (s, 3H), 3.06 (t, *J* = 7.7 Hz, 2H), 2.97 (t, *J* = 7.8 Hz, 2H).

¹³C NMR (151 MHz, CDCl₃): δ 169.1, 162.0, 149.2, 147.9, 134.9, 131.9, 129.1, 124.1, 120.3, 111.7, 111.5, 56.1, 56.0, 33.2, 30.4.

TLC: R_f = 0.60 (1:1 hexanes/ethyl acetate)

Compound S10



Following the General Procedure 1 with 1-(*tert*-butoxycarbonyl)pyrrolidine-3-carboxylic acid (2.15 g, 10 mmol), *N*-hydroxyphthalimide (1.63 g, 10 mmol), DMAP (122 mg, 1 mmol) and DIC (1.72 mL, 11 mmol) in DCM (50 mL) at rt for 2 h afforded 2.35 g (65%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

Physical State: White solid


¹H NMR (600 MHz, CDCl₃): δ 7.89 (dd, J = 5.5, 3.1 Hz, 2H), 7.80 (dd, J = 5.5, 3.1 Hz, 2H), 3.84 – 3.35 (m, 5H), 2.35 (s, 2H), 1.47 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): *Major Rotamer* δ 169.8, 161.9, 154.2, 135.0, 129.0, 124.2, 80.0, 48.0, 45.0, 40.8, 29.5, 29.6.

Minor Rotamer δ 169.8, 161.9, 154.2, 135.0, 129.0, 124.2, 80.0, 47.7, 45.3, 39.9, 29.5, 29.6.

TLC: R_f = 0.43 (1:1 hexanes/ethyl acetate)

Compound S12



Following the General Procedure 1 with 3-(*tert*-butoxycarbonyl)thiazolidine-4-carboxylic acid (2.00 g, 8.58 mmol), *N*-hydroxyphthalimide (1.40 g, 8.58 mmol), DMAP (105 mg, 0.86 mmol) and DIC (1.48 mL, 9.44 mmol) in DCM (40 mL) at rt for 2 h afforded 2.19 g (67%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).


Physical State: White solid

¹H NMR (600 MHz, MeOD): δ 7.97 – 7.86 (m, 4H), 5.25 – 5.05 (m, 1H), 4.62 (d, J = 9.2 Hz, 1H), 4.58 – 4.45 (m, 1H), 3.72 – 3.53 (m, 1H), 3.46 (dd, J = 12.3, 3.9 Hz, 1H), 1.51 (s, 9H).

¹³C NMR (151 MHz, MeOD): δ 169.2, 163.0, 154.5, 136.4, 130.1, 125.0, 83.5, 61.1, 50.1, 35.7, 28.3.

TLC: R_f = 0.73 (1:1 hexanes/ethyl acetate)

Compound S22



Following the General Procedure 1 with chenodeoxycholic acid (5.00 g, 12.7 mmol), *N*-hydroxyphthalimide (2.07 g, 12.7 mmol), DMAP (155 mg, 1.27 mmol) and DCC (2.89 g, 12.7 mmol) in DCM (60 mL) at rt for 6 h afforded 4.94 g (72%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).


Physical State: White solid

¹H NMR (600 MHz, CDCl₃): δ 7.88 (s, 2H), 7.78 (d, *J* = 8.6 Hz, 2H), 3.85 (q, *J* = 3.1 Hz, 1H), 3.46 (ddd, *J* = 11.1, 6.7, 4.4 Hz, 1H), 2.71 (ddd, *J* = 16.0, 9.5, 5.2 Hz, 1H), 2.59 (ddd, *J* = 16.0, 9.1, 7.0 Hz, 1H), 2.21 (td, *J* = 13.0, 11.2 Hz, 1H), 2.02 – 1.88 (m, 4H), 1.88 – 1.78 (m, 2H), 1.76 – 1.44 (m, 9H), 1.43 – 1.06 (m, 9H), 1.03 – 0.94 (m, 1H), 1.00 (d, *J* = 6.4 Hz, 3H), 0.91 (s, 3H), 0.69 (s, 3H).

¹³C NMR (151 MHz, CDCl₃): δ 170.2, 162.1, 134.9, 129.1, 124.1, 72.2, 68.7, 55.9, 42.9, 41.6, 40.0, 39.8, 39.6, 35.5, 35.4, 35.2, 34.7, 33.0, 30.8, 30.8, 28.3, 28.2, 23.9, 22.9, 20.7, 18.4, 11.9.

TLC: *R*_f = 0.62 (ethyl acetate)

Compound 39



Following the General Procedure 1 with *N*-(*tert*-Butoxycarbonyl)-L-glutamic acid 1-benzyl ester (10.0 g, 29.6 mmol), *N*-hydroxyphthalimide (4.83 g, 29.6 mmol), DMAP (361.6 mg, 2.96 mmol) and DIC (5.1 mL, 32.6 mmol) in DCM (180 mL) at rt for 2 h afforded 12.6 g (88%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).


Physical State: White crystalline solid

¹H NMR (600 MHz, CDCl₃): δ 7.89 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.79 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.41 – 7.31 (m, 5H), 5.22 (s, 2H), 5.20 (br s, 1H), 4.45 (s, 1H), 2.78 (ddd, *J* = 17.0, 9.5, 6.2 Hz, 1H), 2.70 (ddd, *J* = 17.0, 9.5, 5.9 Hz, 1H), 2.36 (s, 1H), 2.12 (dddd, *J* = 14.2, 9.5, 8.3, 5.9 Hz, 1H), 1.44 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 171.7, 169.0, 161.9, 155.5, 135.2, 134.9, 129.0, 128.8, 128.7, 128.5, 124.2, 80.4, 67.6, 52.8, 28.4, 27.8, 27.5.

TLC: R_f = 0.45 (1:1 hexanes/ethyl acetate)

Compound S27



Following the General Procedure 1 with 1-methyl-2-oxabicyclo[2.2.1]heptane-4-carboxylic acid (1.5 g, 9.6 mmol), *N*-hydroxyphthalimide (1.57 g, 9.6 mmol), (117 mg, 0.96 mmol) and DIC (1.65 mL, 10.56 mmol) in DCM (50 mL) at rt for 2 h afforded 1.99 g (69%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).


Physical State: White solid

¹H NMR (500 MHz, CDCl₃): δ 7.88 (dd, *J* = 5.3, 3.2 Hz, 2H), 7.79 (dd, *J* = 5.3, 3.2 Hz, 2H), 4.20 (dd, *J* = 6.9, 3.6 Hz, 1H), 3.96 (d, *J* = 6.9 Hz, 1H), 2.32 (tdd, *J* = 11.9, 5.8, 3.5 Hz, 1H), 2.15 (dddd, *J* = 9.5, 7.2, 5.2, 2.7 Hz, 1H), 2.12 – 2.08 (m, 1H), 2.04 (d, *J* = 9.8 Hz, 1H), 1.83 (ddd, *J* = 14.7, 8.6, 3.6 Hz, 2H), 1.46 (s, 3H).

¹³C NMR (151 MHz, CDCl₃): δ 169.24, 161.96, 134.97, 129.09, 124.17, 85.96, 74.75, 52.06, 46.42, 36.63, 33.20, 18.92.

TLC: *R*_f = 0.58 (1:1 ethyl acetate/hexanes)

Compound S30



Following the General Procedure 1 with (4*S*)-1-(*tert*-butoxycarbonyl)-4-((*tert*-butyldimethylsilyl)oxy)pyrrolidine-2-carboxylic acid (100 mg, 0.29 mmol), *N*-hydroxyphthalimide (47.3 mg, 0.29 mmol), DMAP (4 mg, 0.03 mmol) and DIC (0.05 mL, 0.32 mmol) in DCM (1 mL) at rt for 2 h afforded 72 mg (51%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

Physical State: White solid


¹H NMR (600 MHz, CDCl₃): *Major Rotamer* δ 7.87 (dd, $J = 5.5, 3.0$ Hz, 2H), 7.78 (dd, $J = 5.5, 3.1$ Hz, 2H), 4.64 (dd, $J = 9.2, 4.9$ Hz, 1H), 4.48 – 4.36 (m, 1H), 3.70 (dd, $J = 11.0, 5.5$ Hz, 1H), 3.40 (ddd, $J = 10.9, 4.2, 0.9$ Hz, 1H), 2.58 (ddd, $J = 12.8, 9.2, 5.3$ Hz, 1H), 2.36 (dt, $J = 13.0, 4.7$ Hz, 1H), 1.50 (s, 9H), 0.85 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H).

Minor Rotamer δ 7.87 (dd, $J = 5.5, 3.0$ Hz, 2H), 7.78 (dd, $J = 5.5, 3.1$ Hz, 2H), 4.70 (dd, $J = 9.0, 5.5$ Hz, 1H), 4.48 – 4.36 (m, 1H), 3.64 (dd, $J = 10.8, 5.7$ Hz, 1H), 3.32 (dd, $J = 10.8, 4.7$ Hz, 1H), 2.58 (ddd, $J = 12.8, 9.2, 5.3$ Hz, 1H), 2.36 (dt, $J = 13.0, 4.7$ Hz, 1H), 1.47 (s, 9H), 0.87 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H).

¹³C NMR (151 MHz, CDCl₃): δ 168.5, 161.7, 153.6, 134.8, 129.1, 124.0, 81.3, 69.8, 55.9, 54.1, 39.6, 28.2, 25.8, 18.1 -4.8, -4.9.

TLC: $R_f = 0.91$ (1:1 ethyl acetate/hexanes)

Compound S31



Following the General Procedure 1 with gibberellic acid (1 g, 2.88 mmol), *N*-hydroxyphthalimide (470 mg, 2.88 mmol), DMAP (35 mg, 0.29 mmol) and DCC (656 mg, 3.18 mmol) in THF (14 mL) at rt for 3 h afforded 1.06 g (72%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).


Physical State: Pale yellow solid

¹H NMR (500 MHz, CDCl₃): δ 7.89 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.81 (dd, *J* = 5.5, 3.1 Hz, 2H), 6.34 (d, *J* = 9.3 Hz, 1H), 5.93 (dd, *J* = 9.3, 3.7 Hz, 1H), 5.35 (s, 1H), 5.07 (s, 1H), 4.22 (dd, *J* = 6.7, 3.8 Hz, 1H), 3.30 (d, *J* = 10.9 Hz, 1H), 3.15 (d, *J* = 11.0 Hz, 1H), 2.81 (d, *J* = 15.7 Hz, 1H), 2.29 (d, *J* = 15.5 Hz, 1H), 2.14 (dd, *J* = 11.5, 7.1 Hz, 2H), 2.07 – 1.91 (m, 3H), 1.90 – 1.79 (m, 2H), 1.71 (d, *J* = 8.7 Hz, 2H), 1.42 (s, 3H).

¹³C NMR (151 MHz, CDCl₃): δ 178.1, 168.9, 161.9, 156.8, 135.1, 132.7, 132.7, 128.9, 124.2, 108.1, 90.4, 78.3, 69.8, 53.7, 53.5, 51.6, 50.9, 48.3, 44.7, 42.9, 38.0, 17.1, 14.5.

TLC: R_f = 0.58 (1:3 hexanes/ethyl acetate)

Compound S32



To a stirring solution of sodium 2-fluoroacetate (1.0 g, 10 mmol, 1.0 equiv.) in DMF (10 mL) was added 2-(1,3-dioxoisindolin-2-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (5.7 g, 14 mmol, 1.4 equiv.). The contents were allowed to stir until complete (measure by TLC). Upon completion, the reaction mixture was diluted in ethyl acetate. The organic material was washed with water (3 x 20 mL) followed by brine (20 ml). The organics were dried over magnesium sulfate, filtered and concentrated to afford a pale yellow paste. The residue was purified via column chromatography (hexanes to 1:1 hexanes/ethyl acetate) to afford **S32** as a white solid (1.23 g, 55% yield). *Note:* this compound was stored in a refrigerator to prevent decomposition.

Physical State: White solid


¹H NMR (500 MHz, CDCl₃): δ 7.91 (dd, $J = 5.5, 3.1$ Hz, 2H), 7.82 (dd, $J = 5.5, 3.1$ Hz, 2H), 5.28 (d, $J_{HF} = 46.3$ Hz, 2H).

¹³C NMR (151 MHz, CDCl₃): δ 164.39 (d, $J_{CF} = 22.9$ Hz), 161.47, 135.23, 128.86, 124.40, 76.08 (d, $J_{CF} = 186.4$ Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ -236.73.

TLC: $R_f = 0.28$ (1:1 hexanes/ethyl acetate)

Compound S33



Following the General Procedure 1 with 2-(phenylcarbamoyl)butanoic acid (2.07 g, 10 mmol), *N*-hydroxyphthalimide (1.63 g, 10 mmol), DMAP (122 mg, 1 mmol) and DIC (1.7 mL, 11 mmol) in DCM (40 mL) at rt for 3 h afforded 321 mg (91%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).


Physical State: White solid

¹H NMR (500 MHz, CDCl₃): δ 8.38 (br, 1H), 7.93 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.83 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.66 – 7.58 (m, 2H), 7.39 – 7.31 (m, 2H), 7.15 (tt, *J* = 7.3, 1.2 Hz, 1H), 3.73 (dd, *J* = 8.6, 5.8 Hz, 1H), 2.35 – 2.14 (m, 2H), 1.18 (t, *J* = 7.5 Hz, 3H).

¹³C NMR (151 MHz, CDCl₃): δ 168.46, 164.05, 161.99, 137.51, 135.30, 129.19, 128.91, 125.10, 124.46, 120.62, 52.65, 24.30, 11.79.

TLC: *R_f* = 0.44 (1:1 hexanes/ethyl acetate)

Compound 52



Following the General Procedure 1 with 2-((*tert*-butoxycarbonyl)amino)-4,5,6,7-tetrahydrobenzo[*d*]thiazole-6-carboxylic acid (450 mg, 1.51 mmol), *N*-hydroxyphthalimide (242.3 mg, 1.51 mmol), DMAP (18.5 mg, 0.15 mmol) and DCC (342.4 mg, 1.66 mmol) in THF (6 mL) at rt for 3 h afforded 342 mg (inseparable 5:1 mixture of **52** and DCC-urea byproduct, 46% yield of desired compound, 91 wt/wt%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). This compound was used in the subsequent step without further purification.

Physical State: White solid


¹H NMR (600 MHz, CDCl₃): δ 7.89 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.80 (dd, *J* = 5.5, 3.1 Hz, 2H), 3.26 – 3.05 (m, 3H), 2.96 (dt, *J* = 16.8, 4.7 Hz, 1H), 2.79 (ddd, *J* = 16.8, 10.0, 5.6 Hz, 1H), 2.45 (dq, *J* = 9.8, 3.2 Hz, 1H), 2.15 (tdd, *J* = 10.6, 8.3, 5.2 Hz, 1H), 1.54 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 171.0, 162.0, 159.2, 152.6, 143.5, 135.0, 129.1, 124.2, 118.8, 82.7, 38.0, 28.4, 25.4, 25.1.

TLC: *R*_f = 0.26 (1:1 hexanes/ethyl acetate)

Synthesis of Other Starting Materials

Compound 56



To a stirring solution of methyl 4-bromo-1*H*-pyrrolo[2,3-*b*]pyridine-3-carboxylate (1.00 g, 3.92 mmol, 1.0 equiv.) and potassium carbonate (1.08 g, 7.84 mmol, 2.0 equiv.) in DMF (10 mL) was added methyl iodide (1.22 mL, 19.60 mmol, 5.0 equiv.). The resulting suspension was allowed to stir vigorously at room temperature for 3 hours. Upon completion (monitored by LCMS), the reaction mixture was diluted with water (10 mL). The organic material was extracted (3 x 20 mL) with ethyl acetate. The combined organic material was washed with brine, dried over Mg₂SO₄ and concentrated to afford an orange residue. The crude material was purified via silica gel column chromatography (25 – 50% ethyl acetate/hexanes) to afford **56** as a light orange solid (713 mg, 68% yield).

Physical State: Light orange solid


¹H NMR (600 MHz, CDCl₃): δ 8.13 (d, *J* = 5.1 Hz, 1H), 7.98 (s, 1H), 7.45 (d, *J* = 5.1 Hz, 1H), 3.91 (s, 3H), 3.89 (s, 3H).

¹³C NMR (151 MHz, CDCl₃): δ 163.7, 148.9, 143.8, 136.9, 125.6, 123.5, 118.9, 106.3, 51.5, 32.3.

HRMS (ESI-TOF): calculated for C₁₀H₉BrN₂O₂ [M+H]⁺: 268.9926, found: 268.9931.

TLC: R_f = 0.56 (1:1 ethyl acetate/hexanes)


General Procedure 2: Ag-Ni Electrocatalytic Decarboxylative Arylation (0.4 mmol scale)




To an oven dried 5 mL ElectraSyn 2.0 vial, redox active ester (RAE) (0.4 mmol, 1 equiv.), aryl halide (0.6 mmol, 1.5 equiv.), NiCl₂·6H₂O (19.0 mg, 0.08 mmol, 0.2 equiv.), and 2,2'-bipyridine (12.5 mg, 0.08 mmol, 0.2 equiv.) were all directly added as solids/oils. Anhydrous NMP or DMF was then added (3 mL) via syringe. The contents of the vial were allowed to stir until all solids were dissolved (roughly 10 minutes. See picture below). AgNO₃ (34.0 mg, 0.20 mmol, 0.5 equiv.) was then added to the reaction mixture directly as a solid. The vial was closed with an ElectraSyn 2.0 vial cap with a magnesium sacrificial anode and a 100 ppi RVC cathode (3 mm x 7 mm x 51 mm). The vial was then placed on an IKA ElectraSyn 2.0 stir plate and electrolysis was set to 12 mA, 0.4 mmol, 2.5 to 4.0 F/mol providing 5.4 A/m² current density. The reaction underwent the programmed electrolysis open to air. After completion of the reaction, the reaction was transferred to a separatory funnel, the electrodes were rinsed with ethyl acetate (5 mL) and sat'd. aq. NaHCO₃ (10 mL) (note: water can be used instead if substrate is sensitive) was *slowly* added. The aqueous layer was extracted with ethyl acetate (3 X 10 mL). The combined organics were washed successively with distilled water (2 X 10 mL) then brine (1 X 10 mL), then dried over magnesium sulfate before being filtered and concentrated via rotary evaporation. The crude oily solid was purified *via* silica gel chromatography to afford the desired product.

Note: It is important to start the reaction immediately after the addition of AgNO₃. If the AgNO₃ sits too long before the electrolysis begins, the yield will be diminished.


Visual Guide for General Procedure 2



Left: Reagents for the Ag-Ni Electrocatalytic DCC. **Center:** Nickel, ligand, arene and RAE weighed out in an Electrasyn 2.0 vial. **Right:** Addition of NMP to the Electrasyn 2.0 vial. Permitted use of Logo is credited to IKA.




Left: Solution of nickel, ligand, RAE and arene after stirring for 10 minutes. **Center:** (optional) removal of the screwcap on the Electrasyn 2.0 **Right:** (optional) removed screwcap on the Electrasyn 2.0 vial. Permitted use of logo is credited to IKA.





Left: Electrasyn 2.0 Cap without electrodes. **Center:** Insertion of the Mg anode on the left side of the cap. **Right:** Attached Mg electrode.




Left: Assembly of the RVC electrode. **Center:** Insertion RVC electrode into the beige clip. **Right:** Attached RVC electrode on the right of the cap.



Left: Select “New Experiments”. **Center:** Select “Constant Current”. **Right:** Set the current to 12 mA. Permitted use of logo is credited to IKA.




Left: Select “No” when prompted about a reference electrode. **Center:** Select “Total Charge”. **Right:** Set the scale to 0.4 mmol and the “equivalents of electrons” to 2.5 F/mol. Permitted use of logo is credited to IKA.




Left: Select “No” when prompted about alternating polarity. **Center:** Select “No” when asked to save experiment. **Right:** Addition of silver nitrate to the homogenous reaction solution. Permitted use of logo is credited to IKA.



Left: Attachment of the cap to the Electrasyn 2.0 vial. **Center:** Attached vial to the Electrasyn 2.0. **Right:** Start of the reaction. Permitted use of logo is credited to IKA.




Left: Heterogenous suspension observed at the start of the reaction. **Center:** Return to homogeneity after 0.5 F/mol has passed. **Right:** Reaction mixture after the first 0.5 F/mol. Permitted use of logo is credited to IKA.



Left: Reaction mixture upon completion. **Center:** Crude reaction mixture partitioned between ethyl acetate in sat'd sodium bicarbonate. **Right:** Combined organic fractions dried over magnesium sulfate. Permitted use of logo is credited to IKA.




General Procedure 3: In Situ Ag-Ni Electrocatalytic Decarboxylative Arylation (0.4 mmol scale)





An oven-dried culture tube equipped with stir bar was charged with carboxylic acid (0.4 mmol, 1 equiv.) and N-hydroxyphthalimide (NHPI) (81.6 mg, 0.50 mmol, 1.25 equiv.). The tube was sealed and purged with argon. The contents of the flask were diluted in anhydrous inhibitor-free THF (0.50 mL). To this solution, DIC (69 μ L, 0.44 mmol, 1.1 equiv.) was added and the reaction was allowed to stir at room temperature until complete formation of redox active ester (1-3 hours, by TLC) and a white solid was observed. To a separate culture tube containing a stir bar was added NiCl₂·6H₂O (19 mg, 0.08 mmol, 0.2 equiv.), 2,2'-bipyridine (12.5 mg, 0.08 mmol, 0.20 equiv.) and aryl halide (0.6 mmol, 1.5 equiv.). This tube was evacuated and backfilled three times with argon before the addition of anhydrous NMP or DMF (2.5 mL). This solution was allowed to stir for 20 minutes and a homogeneous, dark green solution developed. This green solution was transferred via syringe into the flask containing the in situ activated ester (white suspension). This green suspension (~ 3 mL) was added to a 5 mL ElectraSyn 2.0 vial under argon containing a magnesium anode, 100 ppi RVC cathode (3 mm x 7 mm x 51 mm), AgNO₃ (34 mg, 0.2 mmol, 0.5 equiv.) and stir bar. After addition electrolysis was immediately started. The electrochemical reaction was performed using an ElectraSyn 2.0 constant current conditions with the settings as follows: 12 mA, 0.4 mmol, 2.5 to 4.0 F/mol providing 5.4 A/m² current density. After completion of the reaction, the reaction was transferred to a separatory funnel, the electrodes were rinsed with ethyl acetate (5 mL) and water (10 mL) was slowly added. The aqueous layer was extracted with ethyl acetate (3 X 10 mL). The combined organics were washed successively with distilled water (2 X 10 mL) then brine (1 X 10 mL), then dried over magnesium sulfate before

being filtered and concentrated via rotary evaporation. The crude oily solid was purified silica gel chromatography.


Visual Guide




Left: Carboxylic acid and NHPI weighed in a culture tube equipped with stir bar. **Center:** Vacuum and argon purging cycles. **Right:** Carboxylic acid and NHPI dissolved in THF.





Left: Addition of DIC to the reaction mixture. **Center:** In situ activation after 2 minutes (yellow). **Right:** In situ activation after 1 hour (heterogenous white).





Left: Nickel, ligand and aryl halide weighed out in a culture tube. **Center:** Vacuum and argon purging of the reagents for catalyst solution. **Right:** Catalyst solution stirring in NMP



Left: Silver nitrate weighed out in a 5 mL Electrasyn vial. **Center:** Vacuum and purging of the Electrasyn vial with argon. **Right:** Transfer of of the catalyst solution via syringe to the in situ RAE synthesis.




Left: Addition of the catalyst solution to the in situ RAE synthesis. **Center:** Combined catalyst and RAE solutions. **Right:** Combined solution added to the Electrasyn vial with silver before electrolysis. Permitted use of logo is credited to IKA.



Left: Reaction mixture at the start of the electrolysis. **Center:** Reaction mixture halfway through electrolysis. **Right:** Reaction mixture at the end of electrolysis. Permitted use of logo is credited to IKA.

See visual guide for Procedure 2 for work up

General Procedure 4: Ag-Ni Electrocatalytic Decarboxylative Arylation (5 mmol scale)



To an oven dried 20 mL ElectraSyn 2.0 vial, redox active ester (RAE) (5 mmol, 1 equiv.), aryl halide (7.5 mmol, 1.5 equiv.), NiCl₂·6H₂O (237.8 mg, 1.0 mmol, 0.2 equiv.), and 2,2'-bipyridine (156 mg, 1 mmol, 0.2 equiv.) were all directly added as solids/oils. Anhydrous NMP or DMF was then added (18 mL) via syringe. The contents of the vial were allowed to stir until all solids were dissolved (roughly 10 minutes. See picture below). AgNO₃ (424 mg, 2.5 mmol, 0.5 equiv.) was then added to the reaction mixture directly as a solid. The vial was equipped with an ElectraSyn 2.0 vial cap with a magnesium sacrificial anode and a cylindrical 100 ppi RVC cathode (9 mm diameter, 40 mm length). The RVC electrode was prepared following a literature procedure.²⁸ The vial was then placed on an IKA ElectraSyn 2.0 stir plate and electrolysis was set to 100 mA, 5.0 mmol, 3.5 F/mol providing 10.6 A/m² current density. The reaction underwent the programmed electrolysis open to air. After completion of the reaction, the reaction was transferred to a separatory funnel, the electrodes were rinsed with ethyl acetate (30 mL) and saturated. aq. NaHCO₃ (20 mL) (note: water can be used instead if substrate is sensitive) was *slowly* added. The aqueous layer was extracted with ethyl acetate (3 X 20 mL). The combined organics were washed successively with distilled water (2 X 20 mL) then brine (1 X 20 mL), then dried over magnesium sulfate before being filtered and concentrated via rotary evaporation. The crude oily solid was purified *via* silica gel chromatography to afford the desired product.


Visual Guide



Left: 20 mL Electrasyn Cap with magnesium sacrificial electrode and large RVC electrode with IKA trident. **Center:** Electrodes secured on the 20 mL IKA Electrasyn cap. **Right:** RAE, aryl halide, nickel catalyst and ligand weighed into the vial.




Left: Addition of NMP to the reaction mixture. **Center:** Reaction mixture dissolved in NMP. **Right:** Reaction mixture after the addition of silver nitrate.



Left: Reaction mixture at the outset of electrolysis. **Center:** Reaction mixture after 0.5 F/mol. **Right:** Reaction mixture at the end of electrolysis. Permitted use of logo is credited to IKA.

General Procedure 5: Ag-Ni Electrocatalytic Decarboxylative Arylation in Recirculating Flow (100 mmol)



Making the flow cell components

Except for the magnesium and carbon felt electrodes, all flow cell components were custom built using accessible materials and according to the cut diagrams listed in a separate document. The magnesium anode (1mm, AZ31, Amazon) was hand-cut using a small straight-edge blade to be 8.0 cm wide by 20.0 cm long. A 1.5 x 5.0 cm notch was cut into the left and right sides of the top of the magnesium electrode to create a tab for wire connections and to easily slide the electrode between the screw holes of the rest of the flow assembly. Immediately prior to assembling the reactor, the magnesium anode surface was cleaned using 3M HCl, scrubbed with a sponge, and rinsed with water followed by acetone. The carbon felt cathode (3 mm, PAN Polyacrylonitrile, CERA Materials) was cut to 8.0 x 15.0 cm with scissors.

Flow Reactor Assembly

The flow cell was assembled by first laying the front plate flat with bolts (8 x M8-1.25 x 120 mm, stainless steel, Amazon) inserted and protruding upward. Gaskets, electrodes, flow cell and faceplate were all added according to the additional supplementary files and initially secured loosely with nuts. To prevent leaking, Teflon tape was added to each bolt, prior to tightening with a 7/32nd size Allen key. A Peristaltic pump (Part No. VSH-A603150R, ANKO[®]) equipped with Norprene[®] tubing (I.D. 9.5 mm, Part No. T63-N1R50, ANKO[®]) was installed and secured onto the flow cell inlet using adapters. To ensure a proper hold, additional tubing was added at the inlet and outlet of the flow cell. The flow cell outlet tubing (I.D. 9.5 mm, vinyl) was connected in a similar fashion. Two polypropylene tubes (O.D. 9.5 mm) were inserted into the opposite ends of

the Norprene[®] and vinyl tubing, through two rubber septa and capped onto the reaction vessel. All tubing connections were secured with plastic hose clamps where possible.

A 3-neck round bottom flask was used as the recirculator vessel. The third neck of the round bottom flask was capped with a stopper. The power supply (Model No. KA3005D, KORAD[®]) was attached to each of the electrodes via Alligator clips; red to the magnesium anode (+) and black to the stainless-steel support (carbon felt cathode (-)). Prior to running the reactor with substrate, leak tests were performed at varying flow rates. Leaking was prevented by strongly hand-tightening the bolts and adding Teflon tape where possible. The assembled flow system was rinsed with = N-methyl-2-pyrrolidinone.

Running the Reaction

An oven-dried round bottom flask equipped with stir bar was charged with carboxylic acid (100 mmol, 1 equiv.) and N-hydroxyphthalimide (NHPI) (20.4 g, 125 mmol, 1.25 equiv.). The contents of the flask were diluted in anhydrous inhibitor-free THF (125 mL). To this solution, DIC (17 mL, 110 mmol, 1.1 equiv.) was added dropwise and the reaction was allowed to stir at room temperature until complete formation of redox active ester (3 hours, by TLC).

To the three-necked round bottom flask employed for the flow reservoir NiCl₂·6H₂O (4.75 g, 20 mmol, 0.2 equiv.), 2,2'-bipyridine (3.12 g, 20 mmol, 0.20 equiv.), lithium chloride (4.24 g, 100mmol, 1 equiv.), aryl halide (150 mmol, 1.5 equiv.) and NMP (625 mL) were added. This solution was allowed to stir for 20 minutes resulting in a homogeneous, dark green solution.


The solution containing the in situ activated ester (white suspension) was filtered directly into the flask containing the green solution while continuously stirring to remove excess insoluble urea, which was rinsed with dry THF (3 x 5 mL). Once all the filtrate was added, the round bottom flask was capped and the pump was turned on (40RPM, ~680mL/min, CCW). To the flask, silver nitrate (8.49 g, 50 mmol, 0.5 equiv.) was added.

The power source was turned on with a constant 1 A current.

After completion of the reaction, the flow direction was reversed to ensure all liquid was removed from the cell before then removing the reaction mixture. Once removing the reaction mixture, fresh NMP was used to rinse the system before disassembling the cell. Both the consumed magnesium electrode and carbon felt were disposed. All remaining components were rinsed with acetone and left to air dry.

The reaction was divided into three equal portions and individually transferred to a 1 L separatory funnel. Water (250 mL) and diethyl ether (250 mL) were added to the funnel. The aqueous phase was extracted three times for each portion. The organic phase for all three portions were combined and concentrated to ~500 mL. The resulting solution was washed with brine (3 x 200 mL) to remove the residual NMP then dried over magnesium sulfate before being filtered and concentrated via rotary evaporation. The crude oil was purified silica gel chromatography.

Visual Guide for Recirculating Flow Scale Up




Left: Reagents for the *in situ* RAE synthesis. **Center:** Carboxylic acid added into the flask. **Right:** NHPI added into the flask




Left: Flask submerged into a water bath **Center:** THF is added (125 mL). **Right:** Reaction Mixture after DIC addition.




Left: 1L, Three-necked round bottom flask charged with aryl iodide, $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$, 2,2'-bipyridine and LiCl , submerged in a water bath. **Right:** After addition of NMP (625 mL).



Left: After 3 hours, the RAE solution is transferred to the catalyst solution with a paper filter. **Right:** AgNO_3 is added into the flask.




Electrolysis of the reaction mixture.



Schematic representation of the electrochemical flow reactor.

Parallel Synthesis in IKA E-Hive



The following screen was performed using the IKA E-hive attachment for the Electrasyn 2.0. 24 (6 X 4) 0.05 mmol scale reactions were run in parallel. 12 of which were run where **55** (13.7 mg, 0.05 mmol, 1 equiv.) was screened against the 12 different arenes (0.075 mmol, 1.5 equiv.). The other 12 were run where **56** (20.2 mg, 0.075 mmol, 1.5 equiv) were screened against 12 different RAE's (0.050 mmol, 1 equiv.). These experiments are described in the tables below.

Table S2: Arene screen against 55 (Permitted use of logo is credited to IKA.)





Table S3: RAE screen against 56 (Permitted use of logo is credited to IKA).



Procedure

To 24 stainless steel IKA E-hive vials equipped with stir bar was added silver nitrate (4.25 mg, 0.025 mmol, 0.5 equiv.). To 12 of these vials, 2-bromobenzo[*d*]thiazole (16.1 mg, 0.075 mmol, 1.5 equiv), 2-iodo-5-methoxy-*N*-(pyridin-2-yl)benzamide (26.6 mg, 0.075 mmol, 1.5 equiv.), 5-bromo-2-(methylthio)pyrimidine (15.4 mg, 0.075 mmol, 1.5 equiv.), 2-iodo-3-methylpyridine (16.4 mg, 0.075 mmol, 1.5 equiv.), 2-bromo-6-chloro-3-fluoropyridine (15.7 mg, 0.075 mmol, 1.5 equiv.), *tert*-butyl (7-iodopyrrolo[2,1-*f*][1,2,4]triazin-4-yl)carbamate (27 mg, 0.075 mmol, 1.5 equiv.), *tert*-butyl (4-iodophenyl)carbamate (23.9 mg, 0.075 mmol, 1.5 equiv.), 4-bromo-2-fluorobenzonitrile (15.0 mg, 0.075 mmol, 1.5 equiv.), 4-bromo-1-(phenylsulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridine-2-carbaldehyde (27.4 mg, 0.075 mmol, 1.5 equiv.), 2-bromothiazole (12.3 mg, 0.075 mmol, 1.5 equiv.), 2-bromo-5-methoxypyridine (14.0 mg, 0.075 mmol, 1.5 equiv.), 4-chloro-6-(4-iodo-1*H*-pyrazol-1-yl)pyrimidine (23 mg, 0.075 mmol, 1.5 equiv.) respectively. These 12 vials constitute the arene screen.


Next, the remaining 12 vials were charged with **S27** (15.1 mg, 0.050 mmol, 1.0 equiv.), **S28** (18.7 mg, 0.050 mmol, 1.0 equiv.), **S29** (14.5 mg, 0.050 mmol, 1.0 equiv.), **S30** (24.5 mg, 0.050 mmol, 1.0 equiv.), **S31** (24.6 mg, 0.050 mmol, 1.0 equiv.), **S32** (11.2 mg, 0.050 mmol, 1.0

equiv.), **S33** (17.6 mg, 0.050 mmol, 1.0 equiv.), **S34** (14.5 mg, 0.050 mmol, 1.0 equiv.), **S35** (14.1 mg, 0.050 mmol, 1.0 equiv.), **S36** (13.1 mg, 0.050 mmol, 1.0 equiv.), **S37** (18.0 mg, 0.050, 1.0 equiv.), **S38** (17.5 mg, 0.050 mmol, 1.0 equiv.) respectively. These 12 vials constitute the RAE screen.


A large culture tube equipped with stir bar was charged with **55** (179.4 mg, 0.65 mmol), NiCl₂·6H₂O (31.2 mg, 0.13 mmol) and 2,2'-bipyridine (20.8 mg, 0.13 mmol). Anhydrous NMP (13 mL) was added, and the contents were allowed to stir until homogenous. A second large culture tube was charged with **56** (262.37 mg, 0.65 mmol), NiCl₂·6H₂O (31.2 mg, 0.13 mmol) and 2,2'-bipyridine (20.8 mg, 0.13 mmol). Anhydrous NMP (13 mL) was added, and the contents were allowed to stir until homogenous.

The 24 IKA E-hive vials were placed within the IKA E-hive. 1 mL of the solution containing **55** was added directly to each of the 12 vials of the arene screen. 1 mL of the solution containing **56** was added directly to each of the 12 vials of the RAE screen. Each vial was sealed with a rubber E-hive cap equipped with a commercial graphite cathode. The E-hive was closed and the electrochemical reactions were performed using ElectraSyn 2.0 continuous constant potential conditions with the settings as follows: -4.0 V for 12 hours (the resulting current for each vial ranged from 0.5 mA to 3 mA on average). Upon completion, the rubber caps were removed, and the graphite cathode was washed with ethyl acetate. HPLC/MS was then used to detect product formation. Each reaction mixture was diluted in ethyl acetate, filtered, and concentrated to afford a crude oily solid. Purification and isolation of compounds **57** – **80** was achieved through parallel mass-guided preparative HPLC. Amounts are tabulated graphically in the Table S4.

Table S4: Isolated Amounts of Product from the E-Hive.



Negative Control for E-hive Reactions on Preparative Scale



This coupling failed in the e-hive and fails in the preparative 0.4 mmol scale reaction with the optimized electrode material. Thus, the e-hive is a good predictor for coupling viability between two partners.

Visual Guide for Parallel Synthesis in E-Hive




Left: E-hive vials all containing silver nitrate. The left 12 contain the varying arenes and the right 12 contain the varying RAE's. **Center:** Stock solutions of nickel, ligand and either **55** or **56**. **Right:** Addition of the appropriate stock solution to the E-hive vials. Permitted use of logo is credited to IKA.



Left: E-hive with all reactants present. **Center:** Attachment of the E-hive cap containing the graphite cathode. **Right:** Fully assembled E-hive vial. Permitted use of logo is credited to IKA.



Left: E-hive prior to the start of the electrolysis. **Center:** Closed E-hive. **Right:** Electrochemical parameters for the E-hive (-4.0V applied potential for 12 h). Permitted use of logo is credit to IKA.



Left: Current at the outset of the E-hive screen. **Right:** Contents of the E-hive vials after electrolysis. Permitted use of logo is credit to IKA.

FAQ's

Q: How can the Mg sacrificial electrodes be used multiple times?

A: The Mg electrodes are washed with HCl 3M, water, and acetone. The surface of the electrode is then scraped with a blade.

Q: What are the criteria to decide the reaction solvent?

A: Usually, DMF was employed when high potential with NMP was observed (<10V with electrasyn 2.0 potentiostat). Generally, fused rings, pyrimidines, pyrazines and pyridazines perform better when DMF was used as solvent.

Q: Do these reactions go to full conversion? What if the reaction did not go to full conversion?

A: These reactions typically go to full conversion of the RAE within 2.5 F/mol. If the RAE is not fully consumed after 2.5 F, the electrolysis can be continued until 4 F.

Q: Why is the AgNO₃ added just before the electrolysis?

A: As soon as AgNO₃ is added into the reaction mixture, the photolabile, insoluble salt AgCl is generating, and a white suspension is formed. It is essential for the correct deposition of the Ag nanoparticles to initiate the electrolysis maximum after 3 minutes from the addition of the salt.

Q: Is the reaction water sensitive?

A: The reaction is not water sensitive, as hydrated reagents and technical solvents could be employed.

Q: Is the reaction air sensitive?

A: The reaction with premade RAEs generally provided only around 5% higher yields when carried out under inert atmosphere. However, when the *in-situ* generation of the RAE is carried out, the reaction resulted to be more sensitive to air, leading to 10% yield difference.

Q: Can the reaction be run more concentrated or diluted?

A: The optimization screening revealed that the protocol is not particularly sensitive to concentration. However, it is highly recommended to adjust the current parameter accordingly (e.g. half the concentration, half the current).

Q: What are the typical side products of the reaction?

A: Regarding the RAE, hydrolysis is the most common side product observed. Regarding the halides, dehalogenation is the most common side product observed.

Q: It appears that an exogenous traditional electrolyte is not necessary for the small-scale protocol. What might be serving as the electrolyte(s) in the system?

A: While no traditional electrolyte is needed for this small-scale experimental, there are several possibilities for what may be serving that role. The nickel catalyst itself, may act as an electrolyte as reactions without this catalyst only resulted in very high terminal potentials (>20V). Additionally, since a sacrificial magnesium anode is used in the reaction, a variety of different magnesium salts may serve this role as well including but not limited to Mg(NO₃)₂, MgI₂, MgBr₂ (both from the halide of the aryl electrophile) and Mg(phth)₂ (from radical fragmentation of the redox active ester).

Q: Can this protocol be used to prepare a variety of unnatural amino acids?

A: Yes. Since the redox active esters derived from aspartic and glutamic acid can be readily prepared and used in such couplings, then further applications to the production of more unnatural amino acids should be feasible.

Q: What is the functional group tolerance for this reaction. What are critical limitations?

A: The functional group compatibility of this reaction is high as evidenced by the dozens of substrates reported in this manuscript. A notable limitation of the method is that free amines are not tolerated. This is a limitation general to any use of an activated ester (such as NHPI esters) since they readily form amide bonds in the presence of the amine.


Q: Does this method work with ortho-substituted haloarenes

A: The reaction works well with ortho substituted arenes such as compounds **13**, **15**, **19**, **51**, and **83**.


Q: How do primary, secondary and tertiary RAE's compare in the coupling?

A: Generally, the primary and secondary RAE's appeared to couple with equal efficacy. The tertiary coupling partners were limited to sterically unencumbered tertiary radicals much like bicyclopropanes.

Troubleshooting Guide




Zinc Mediated DCC Control




The reaction was performed in accordance with literature procedure on 0.4 mmol scale of aryl halide.²⁹ Upon completion, the reaction mixture was then diluted with ethyl acetate (3 mL) the mixture was filtered over celite, and an aliquot was analyzed via ¹H NMR with 1,3,5-trimethoxybenzene as an internal standard.

Electrochemically Mediated DCC Control




The reaction was performed in accordance with literature procedure on 0.375 mmol scale of aryl halide.³⁰ Upon completion the reaction mixture was diluted with ethyl acetate (3 mL). The mixture was filtered over celite, and an aliquot was analyzed via ¹H NMR with 1,3,5-trimethoxybenzene as an internal standard.

Reductive Photochemical DCC Control




The reaction was performed in accordance with literature procedure on 0.25 mmol scale of aryl halide.³¹ A BMS-PR-390 photoreactor was used as the light source.³² Upon completion the reaction mixtures were worked up according to the literature procedure. The crude material was purified via preparative Reverse Phase chromatography with the following conditions: Column: XBridge C18, 19 mm x 200 mm, 5 μm particles; Flow Rate: 20 mL/min; Column Temperature: 25 °C. Fraction collection was triggered by MS (ESI +). Fractions containing the desired product were combined and dried via centrifugal evaporation.

Oxidative Photochemical Activation DCC Control



The reaction was performed in accordance with literature procedure.³³ A BMS-PR-450 photoreactor was used as the light source.³² Upon completion the reaction mixtures were worked up according to the literature procedure. The crude material was purified via preparative Reverse Phase chromatography with the following conditions: Column: XBridge C18, 19 mm x 200 mm, 5 μm particles; Flow Rate: 20 mL/min; Column Temperature: 25 °C. Fraction collection was triggered by MS (ESI +). Fractions containing the desired product were combined and dried via centrifugal evaporation.


Positive Control for Oxidative Photochemical Activation DCC Control



Using an exact substrate from the cited paper, the photochemical DCC was reproduced thus ruling out any issue with photochemical reactors.

Prior Attempts at Accessing **51**

Negishi-DCC



Preparation of **53**


iPrMgCl LiCl complex (0.49 mL of a 1.3 M solution in THF; 0.632 mmol, 1.1 equiv.) was added to a solution of 5-bromo-4-cyclopropoxy-2-(methylthio)pyrimidine (150 mg, 0.57 mmol, 1 equiv.) in anhydrous THF (5 mL) at 0 °C. The reaction was stirred at 0 °C for 1 h, after which ZnCl₂ (63 mL of a 1.0 M solution in Et₂O, 1.1 equiv.) was added. The reaction mixture was stirred at RT for 20 min to give a solution of the bis(4-cyclopropoxy-2-(methylthio)pyrimidin-5-yl)zinc (246 mg, 0.575 mmol) in THF; this reagent was used in the next reaction directly.

Coupling reaction

The reaction was performed in accordance with a literature procedure.³⁴ A 10 mL flask was charged with NiCl₂(dme) (9.71 mg, 0.044 mmol, 0.2 equiv.), 4,4'-di-tert-butyl-2,2'-dipyridyl (24 mg, 0.088 mmol, 0.4 equiv.), and **52** (98 mg, 0.221 mmol, 1 equiv.), then was sparged with N₂. Anhydrous DMF (10 mL) was added, and the reaction mixture was stirred for 2 min prior to the addition of **53** (236 mg, 0.552 mmol, 2.5 equiv.) (from the previous reaction) in one portion in


THF. The resulting mixture was stirred at RT overnight. At this point LC-MS did not show the presence of the desired product. The reaction was quenched and discarded.

Zn-Mediated DCC




The reaction was performed in accordance with a literature procedure.²⁹ To an oven-dried flask with a Teflon-coated stir-bar was added $\text{NiBr}_2(\text{dtbbpy})$ (5.9 mg, 0.012 mmol, 0.07 equiv.), **52** (115 mg, 0.258 mmol, 1.5 equiv.), **54** (45 mg, 0.172 mmol, 1 equiv.), Zinc (22.5 mg, 0.345 mmol, 2 equiv.), and DMA (1 mL). The flask was degassed under N_2 3 times and then stirred at rt for 18 hours. LC-MS only showed trace amount of product. The reaction was further stirred at 60 °C for 18 hours. LC-MS still only showed trace amount of product. The reaction quenched and discarded.

Reductive Photochemical Activation



The reaction was performed in accordance with a literature procedure.³¹ To an 8 mL vial equipped with a magnetic stir bar and a rubber septum was added $\text{NiBr}_2(\text{dtbbpy})$ (7.1 mg, 0.015 mmol, 0.1 equiv.), Hantzsch-ester (73.7 mg, 0.291 mmol, 2 equiv.), **52** (97 mg, 0.218 mmol, 1.5 equiv.), **54** (38 mg, 0.146 mmol, 1 equiv.), and DMA (3 mL). The vial was evacuated three times via an inlet needle then purged with argon. The reaction mixture was irradiated for 24 h with two Kessil PR160-purple LED lamps (30 W High Luminous DEX 2100 LED, $\lambda_{\text{max}} = 390 \text{ nm}$). LC-MS only showed trace amount of product. The reaction was quenched and discarded.


Oxidative Photochemical Activation



The reaction was performed in accordance with a literature procedure.³⁵ An oven-dried vial was charged with **56** (25 mg, 0.100 mmol, 1 equiv.) (4,4'-Di-*t*-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-*k*N]phenyl-*k*C]iridium(III) hexafluorophosphate (2.5 mg, 0.002 mmol, 0.02 equiv.), 4,4'-Di-*t*-butyl-2,2'-dipyridyl (1.6 mg, 0.006 mmol), NiCl₂(dme) complex (1 mg, 0.005 mmol, 0.05 equiv.), Cs₂CO₃ (49 mg, 0.15 mmol, 1.5 equiv.), and DMSO (1.5 mL). The reaction mixture was degassed by sparging with N₂ for 10 min, then was stirred in a photoreactor (400 nm light source, 100% intensity, 1000 rpm stirring and 10000 rpm fan speed) for 3 days at RT. At this point, an LC-MS analysis of the reaction mixture did not show any presence of the desired product. The reaction was quenched and discarded.


Optimization of the Ag-Ni Electrocatalytic Decarboxylative Arylation

Table S5: Solvent Screen



entry	solvent	%yield (¹ H-NMR)
1	DMF	16
2	DMA	8
3	NMP	29
4	MeCN	8
5	DMF/THF (4:1)	24
6	DCM	NR
7	NMP/THF (4:1)	25
8	DMI	21


Table S6: Electrode Screen



entry	cathode	Anode	%yield (¹ H-NMR)
1	RVC	Mg	30
2	RVC	Zn	10
3	RVC	Al ^a	37
4	C	Mg	3
5	C	Zn	11
6	C	Al ^a	3


^a High cell resistance, NaI (0.3 equiv.) added.

Table S9: Electrochemical Parameters and Concentration




entry	scale	current	concentration	current/mmol	current density (A/m ²)	%yield (¹ H-NMR)
1	0.2 mmol	12 mA	0.07 M	60	5.4	34
2	0.2 mmol	6 mA	0.07 M	30	2.7	44
3	0.4 mmol	12 mA	0.13 M	30	5.4	43
4	0.4 mmol	6 mA	0.13 M	15	2.7	44
5	0.4 mmol	18 mA	0.13 M	45	8.1	43
6	0.6 mmol	12 mA	0.20 M	20	5.4	36
7	0.6 mmol	18 mA	0.20 M	30	8.1	38

Table S10: Nickel Source Screen



entry	metal source	%yield (¹ H-NMR)
1	$\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$	43
2	$\text{NiCl}_2(\text{dme})$	39
3	$\text{NiBr}_2(\text{dme})$	37
4	$\text{NiBr}_2(\text{PPh}_3)_2$	15
5	$\text{Ni}(\text{NO}_3)_2 \cdot 6\text{H}_2\text{O}$	24

Table S11: Ligand Screen



entry	ligand	%yield ($^1\text{H-NMR}$)
1	L1	43
2	L2	21
3	L3	18
4	L4	33
5	L5	8
6	L6	9
7	L7	30
8	L8	37
9	L9	2
10	L10	0
11	L11	0
12	L12	1
13	L13	0
14	L14	0
15	L15	0
16	L16	0
17	L1 + L15	17






Table S12: Ligand Stoichiometry




entry	ligand mol %	%yield ($^1\text{H-NMR}$)
1	10	43
2	20	10
3	30	0

Table S13: Catalyst Loading




entry	Ni/L mol %	%yield (¹ H-NMR)
1	5	28
2	10	43
3	12	38
4	15	45
5	20	50
6	30	48

Table S14: Arene Stoichiometry




entry	Equiv. Ar-X	%yield (¹ H-NMR)
1	1.00	42
2	1.25	46
3	1.50	50
4	2.00	50

Table S15: RAE Stoichiometry




entry	Equiv. RAE	%yield ($^1\text{H-NMR}$)
1	1.00	42
2	1.50	43
3	2.00	40

Table S16: Control Study (Under Argon)




entry	Modification	%yield ($^1\text{H-NMR}$)
1	none	50 (50 iso.)
2	Ar-I instead of Ar-Br	63
3	No AgNO_3 (Br)	24
4	No AgNO_3 (I)	24
5	No Nickel	0
6	No Ligand	27
7	No Electricity (16 h, RT)	12
8	Under Air	45
9	Zinc (2 equiv.), No Electricity	0

Table S17: Control Study (Open Flask)



entry	Modification	%yield ($^1\text{H-NMR}$)
1	none	45
2	Technical grade solvent	45
3	Ar-I instead of Ar-Br	62
4	No AgNO_3 with Ar-Br	15
5	No AgNO_3 with Ar-I	19
6	No Nickel	0
7	No Ligand	28
8	No Electricity (16 h, RT)	0
9	Zinc (2 equiv.), No Electricity	0


























Table S18: State of the Art Comparisons with Existing Methods to Access 38



entry	equiv. RAE	equiv. Arene	conditions	reference	%yield (isolated)
1	1.5	1.0	NiBr ₂ (diglyme) (7%) dtbbpy (7%) Zn (2 equiv.) DMA, r.t., o/n	[Zn] <i>J. Am. Chem. Soc.</i> 2016 , 138, 5016 - 5019	X = I : N.D. = Br : N.D.
2	1.5	1.0	NiCl ₂ (dme) (10%) dtbbpy (10%) NaI (0.2 M) DMA (+)Zn/(-)RVC 3 mA, 2.0 F/mol	[e-chem] <i>Org Lett</i> , 2019 21, 816 - 820	X = I : N.D. = Br : N.D.
3	2.0	1.0	NiBr ₂ (dtbbpy) (10 mol%) Hantzsch Ester (2 equiv.) DMA, 390 nm, 24 hr	[HE/hv] <i>Chem. Sci.</i> 2021 , 12, 5450 - 5457	X = I : 32% = Br : 26%
4	1.5 (free acid used)	1.0	Ir[dF(CF ₃)ppy] ₂ (dtbbpy)PF ₆ (1 mol%) NiCl ₂ (dme) (5 mol%) dtbbpy (5.25 mol%) Phthalimide (1 equiv.) BTMG (1.5 equiv.) DMSO, 450 nm, 12 hr	[Ir/hv] <i>Science</i> , 2022 , 376 532 - 539	X = I : 2% = Br : 11%
5	1.0	1.5	NiCl ₂ ·6H ₂ O (20 mol%) 2,2'-bpy (20 mol%) AgNO ₃ (0.5 equiv.) NMP, r.t., 12 mA, 2.5 F/mol Mg(+)/(-)RVC [Open Flask]	[Ag/Ni] This work	X = I : 63% = Br : 45%


N.D = Not detected.

Table S19: Comparison of Substrates with and without Silver

 <p>4</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>80%</td><td>39%</td></tr> <tr><td>[no Ag]</td><td>21%</td><td>13%</td></tr> </table>	[Ag/Ni]	80%	39%	[no Ag]	21%	13%	 <p>5</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>47%</td><td>57%</td></tr> <tr><td>[no Ag]</td><td>9%</td><td>9%</td></tr> </table>	[Ag/Ni]	47%	57%	[no Ag]	9%	9%	 <p>6</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>62%</td><td>41%</td></tr> <tr><td>[no Ag]</td><td>68%</td><td>25%</td></tr> </table>	[Ag/Ni]	62%	41%	[no Ag]	68%	25%	 <p>7</p>	<p>!</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>45%</td></tr> <tr><td>[no Ag]</td><td>13%</td></tr> </table>	[Ag/Ni]	45%	[no Ag]	13%		
[Ag/Ni]	80%	39%																													
[no Ag]	21%	13%																													
[Ag/Ni]	47%	57%																													
[no Ag]	9%	9%																													
[Ag/Ni]	62%	41%																													
[no Ag]	68%	25%																													
[Ag/Ni]	45%																														
[no Ag]	13%																														
 <p>8</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>55%</td><td>27%</td></tr> <tr><td>[no Ag]</td><td>5%</td><td>4%</td></tr> </table>	[Ag/Ni]	55%	27%	[no Ag]	5%	4%	 <p>9</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>84%</td><td>14%</td></tr> <tr><td>[no Ag]</td><td>17%</td><td>0%</td></tr> </table>	[Ag/Ni]	84%	14%	[no Ag]	17%	0%	 <p>10</p>	<p>Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>56%</td></tr> <tr><td>[no Ag]</td><td>0%</td></tr> </table>	[Ag/Ni]	56%	[no Ag]	0%	 <p>11</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>61%</td><td>52%</td></tr> <tr><td>[no Ag]</td><td>26%</td><td>15%</td></tr> </table>	[Ag/Ni]	61%	52%	[no Ag]	26%	15%		
[Ag/Ni]	55%	27%																													
[no Ag]	5%	4%																													
[Ag/Ni]	84%	14%																													
[no Ag]	17%	0%																													
[Ag/Ni]	56%																														
[no Ag]	0%																														
[Ag/Ni]	61%	52%																													
[no Ag]	26%	15%																													
 <p>12</p>	<p>Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>38%</td></tr> <tr><td>[no Ag]</td><td>0%</td></tr> </table>	[Ag/Ni]	38%	[no Ag]	0%	 <p>15</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>38%</td><td>31%</td></tr> <tr><td>[no Ag]</td><td>12%</td><td>6%</td></tr> </table>	[Ag/Ni]	38%	31%	[no Ag]	12%	6%	 <p>16</p>	<p>!</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>44%</td></tr> <tr><td>[no Ag]</td><td>0%</td></tr> </table>	[Ag/Ni]	44%	[no Ag]	0%	 <p>18</p>	<p>Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>65%</td></tr> <tr><td>[no Ag]</td><td>0%</td></tr> </table>	[Ag/Ni]	65%	[no Ag]	0%	 <p>19</p>	<p>Cl</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>61%</td></tr> <tr><td>[no Ag]</td><td>0%</td></tr> </table>	[Ag/Ni]	61%	[no Ag]	0%
[Ag/Ni]	38%																														
[no Ag]	0%																														
[Ag/Ni]	38%	31%																													
[no Ag]	12%	6%																													
[Ag/Ni]	44%																														
[no Ag]	0%																														
[Ag/Ni]	65%																														
[no Ag]	0%																														
[Ag/Ni]	61%																														
[no Ag]	0%																														
 <p>20</p>	<p>Cl</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>51%</td></tr> <tr><td>[no Ag]</td><td>16%</td></tr> </table>	[Ag/Ni]	51%	[no Ag]	16%	 <p>21</p>	<p>Cl</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>41%</td></tr> <tr><td>[no Ag]</td><td>0%</td></tr> </table>	[Ag/Ni]	41%	[no Ag]	0%	 <p>22</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>42%</td><td>22%</td></tr> <tr><td>[no Ag]</td><td>17%</td><td>3%</td></tr> </table>	[Ag/Ni]	42%	22%	[no Ag]	17%	3%	 <p>23</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>32%</td><td>16%</td></tr> <tr><td>[no Ag]</td><td>4%</td><td>2%</td></tr> </table>	[Ag/Ni]	32%	16%	[no Ag]	4%	2%				
[Ag/Ni]	51%																														
[no Ag]	16%																														
[Ag/Ni]	41%																														
[no Ag]	0%																														
[Ag/Ni]	42%	22%																													
[no Ag]	17%	3%																													
[Ag/Ni]	32%	16%																													
[no Ag]	4%	2%																													
 <p>24</p>	<p>!</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>20%</td></tr> <tr><td>[no Ag]</td><td>5%</td></tr> </table>	[Ag/Ni]	20%	[no Ag]	5%	 <p>25</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>36%</td><td>20%</td></tr> <tr><td>[no Ag]</td><td>14%</td><td>8%</td></tr> </table>	[Ag/Ni]	36%	20%	[no Ag]	14%	8%	 <p>26</p>	<p>Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>49%</td></tr> <tr><td>[no Ag]</td><td>0%</td></tr> </table>	[Ag/Ni]	49%	[no Ag]	0%	 <p>27</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>58%</td><td>6%</td></tr> <tr><td>[no Ag]</td><td>0%</td><td>0%</td></tr> </table>	[Ag/Ni]	58%	6%	[no Ag]	0%	0%				
[Ag/Ni]	20%																														
[no Ag]	5%																														
[Ag/Ni]	36%	20%																													
[no Ag]	14%	8%																													
[Ag/Ni]	49%																														
[no Ag]	0%																														
[Ag/Ni]	58%	6%																													
[no Ag]	0%	0%																													
 <p>28</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>61%</td><td>33%</td></tr> <tr><td>[no Ag]</td><td>20%</td><td>4%</td></tr> </table>	[Ag/Ni]	61%	33%	[no Ag]	20%	4%	 <p>29</p>	<p>! Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>43%</td><td>12%</td></tr> <tr><td>[no Ag]</td><td>26%</td><td>0%</td></tr> </table>	[Ag/Ni]	43%	12%	[no Ag]	26%	0%	 <p>30</p>	<p>Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>31%</td></tr> <tr><td>[no Ag]</td><td>8%</td></tr> </table>	[Ag/Ni]	31%	[no Ag]	8%	 <p>31</p>	<p>Br</p> <table border="1"> <tr><td>[Ag/Ni]</td><td>34%</td></tr> <tr><td>[no Ag]</td><td>12%</td></tr> </table>	[Ag/Ni]	34%	[no Ag]	12%				
[Ag/Ni]	61%	33%																													
[no Ag]	20%	4%																													
[Ag/Ni]	43%	12%																													
[no Ag]	26%	0%																													
[Ag/Ni]	31%																														
[no Ag]	8%																														
[Ag/Ni]	34%																														
[no Ag]	12%																														

Procedures and Characterization of Ag-Ni Electrocatalytic Decarboxylative Arylation Products

Compound 1



Following the General Procedure 2 with **2** (179.4 mg, 0.4 mmol) and 4-iodophenol (132.0 mg, 0.6 mmol) or 4-bromophenol (103.8 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 71.0 mg (51%) and 11.2 mg (8%) respectively of the title compound after purification by column chromatography (2:1 hexanes/ethyl acetate).

Flow

Following the General Procedure 5 with (*S*)-5-(*tert*-butoxy)-4-((*tert*-butoxycarbonyl)amino)-5-oxopentanoic acid (30.3 g, 100 mmol) and 4-iodophenol (33.0 g, 150 mmol) in NMP (625 mL) for 4.5 F/mol afforded 15.0 g (43%) of the title compound after purification by column chromatography (3:1 hexanes/ethyl acetate).

Physical State: White Solid


¹H NMR (600 MHz, CDCl₃): δ 7.02 (d, *J* = 8.0 Hz, 2H), 6.75 (d, *J* = 7.9 Hz, 2H), 5.26 (s, 1H), 5.10 (d, *J* = 8.3 Hz, 1H), 4.22 (q, *J* = 7.0 Hz, 1H), 2.65 – 2.49 (m, 2H), 2.08 – 1.98 (m, 1H), 1.86 (dt, *J* = 13.1, 6.5 Hz, 1H), 1.47 (s, 9H), 1.45 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 172.1, 155.6, 154.2, 133.2, 129.6, 115.5, 82.1, 80.0, 54.0, 35.2, 30.8, 28.5, 28.2.

HRMS (ESI-TOF): calculated for C₁₉H₂₉NO₅ [M+H]⁺: 352.2124 found: 352.2115.

TLC: R_f = 0.40 (2:1 hexanes/ethyl acetate)

Compound 4



Following the General Procedure 2 with **S1** (132.5 mg, 0.4 mmol) and 4-iodoanisole (140.4 mg, 0.6 mmol) or 4-bromoanisole (112.0 mg, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 79.1 mg (80%) and 38.7 mg (39%) respectively of the title compound after purification by column chromatography (15:1 hexanes/ethyl acetate).

Physical State: Colorless oil

d.r.: 1.8:1

¹H NMR (600 MHz, CDCl₃): *Major diastereomer:* δ 7.12 (d, *J* = 8.5 Hz, 2H), 6.86 – 6.81 (m, 2H), 3.79 (s, 3H), 3.69 (s, 3H), 2.47 (tt, *J* = 12.0, 3.6 Hz, 1H), 2.35 (tt, *J* = 12.2, 3.6 Hz, 1H), 2.09 (dd, 14.1, 3.7 Hz, 2H), 1.95 (dd, 13.8, 3.5 Hz, 2H), 1.61 – 1.54 (m, 2H), 1.44 (qd, *J* = 12.8, 3.2 Hz, 2H).

Minor diastereomer: δ 7.12 (d, *J* = 8.5 Hz, 2H), 6.86 – 6.81 (m, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 2.72 – 2.68 (m, 1H), 2.48 (tt, *J* = 12.0, 3.6 Hz, 1H), 2.26 – 2.20 (m, 2H), 1.78 – 1.72 (m, 2H), 1.68 – 1.61 (m, 4H).


¹³C NMR (151 MHz, CDCl₃): *Major diastereomer:* δ 176.6, 158.0, 139.2, 127.7, 113.9, 55.4, 51.7, 43.1, 42.8, 33.6, 29.5.

Minor diastereomer: δ 175.7, 157.9, 139.4, 127.8, 113.8, 53.6, 51.7, 42.8, 39.0, 30.8, 27.7.

HRMS (ESI-TOF): calculated for C₁₅H₂₁O₃ [M+H]⁺: 249.1491 found: 249.1492.


TLC: R_f = 0.69 (4:1 hexanes/ethyl acetate)

Compound 5




Following the General Procedure 2 with **S2** (105.0 mg, 0.4 mmol) and 4-iodotoluene (130.8 mg, 0.6 mmol) or 4-bromotoluene (102.6 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 30.1 mg (47%) and 36.9 mg (57%) respectively of the title compound after purification by column chromatography (19:1 hexanes/ethyl acetate). The spectroscopic data matched the literature.³⁶

Compound 6



Following the General Procedure 2 with **S3** (114.0 mg, 0.4 mmol) and 2-(4-iodophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (198.0 mg, 0.6 mmol) or 2-(4-bromophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (169.8 mg, 0.6 mmol) in DMF (3 mL) for 2.5 F/mol afforded 74.0 mg (62%) and 48.9 mg (41%) respectively of the title compound after purification by column chromatography (20:1 hexanes/ethyl acetate). The spectroscopic data matched the literature.³⁷

Compound 7



Following the General Procedure 2 with **S4** (173.8 mg, 0.4 mmol) and *N*-(2-bromo-5-iodophenyl)acetamide (203.9 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 82.3 mg (45%) of the title compound after purification by column chromatography (2:1 hexanes/ethyl acetate).

Physical State: White solid


¹H NMR (600 MHz, CDCl₃): δ 8.18 (s, 1H), 7.56 (s, 1H), 7.42 (d, *J* = 8.2 Hz, 1H), 6.81 (d, *J* = 8.3 Hz, 1H), 5.02 (d, *J* = 8.1 Hz, 1H), 4.40 (q, *J* = 6.8 Hz, 1H), 3.07 (dd, *J* = 14.1, 5.9 Hz, 1H), 2.95 (dd, *J* = 14.0, 6.4 Hz, 1H), 2.21 (s, 3H), 1.42 (s, 9H), 1.40 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 170.8, 168.1, 155.1, 137.4, 135.6, 132.0, 126.3, 123.0, 111.5, 82.4, 79.8, 54.7, 38.3, 28.4, 28.1, 25.0.

HRMS (ESI-TOF): calculated for C₂₀H₂₉BrN₂O₅ [M+Na]⁺: 479.1158 found: 479.1152.

TLC: R_f = 0.25 (2:1 hexanes/ethyl acetate)

Compound 8



Following the General Procedure 2 with **S5** (305.9 mg, 0.4 mmol) and 4-iodobenzonitrile (137.4 mg, 0.6 mmol) or 4-bromobenzonitrile (109.2 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 148.9 mg (55%) and 73.1 mg (27%) respectively of the title compound after purification by column chromatography (1:1 hexanes/ethyl acetate).

Physical State: White solid


¹H NMR (600 MHz, CDCl₃): δ 7.76 (d, *J* = 7.6 Hz, 2H), 7.61 (t, *J* = 6.6 Hz, 2H), 7.54 (d, *J* = 7.9 Hz, 2H), 7.46 (s, 1H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.33 (dd, *J* = 6.6, 2.0 Hz, 4H), 7.33 – 7.30 (m, 5H), 7.29 (d, *J* = 1.7 Hz, 2H), 7.23 (d, *J* = 7.9 Hz, 2H), 7.02 (d, *J* = 7.7 Hz, 7H), 6.27 (s, 1H), 5.09 (q, *J* = 5.8 Hz, 1H), 4.42 – 4.28 (m, 2H), 4.22 (t, *J* = 7.5 Hz, 1H), 3.16 (dd, *J* = 14.6, 4.7 Hz, 1H), 2.84 (dd, *J* = 14.7, 5.5 Hz, 1H).

¹³C NMR (151 MHz, CDCl₃): δ 156.1, 148.3, 144.2, 144.0, 142.2, 141.4, 138.7, 136.4, 132.1, 129.7, 128.3, 128.2, 127.8, 127.1, 125.3, 120.2, 120.1, 119.1, 110.7, 67.0, 55.2, 47.4, 34.2.

HRMS (ESI-TOF): calculated for C₄₆H₃₆N₄O₂ [M+H]⁺: 677.2917 found: 677.2914.

TLC: R_f = 0.31 (1:1 hexanes/ethyl acetate)

Compound 9



Following the General Procedure 2 with **S6** (142.1 mg, 0.4 mmol) and 4-(4-iodophenyl)morpholine (173.5 mg, 0.6 mmol) or 4-(4-bromophenyl)morpholine (145.3 mg, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 109.7 mg (84%) and 18.0 mg (14%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 10:1 to 5:1).

Physical State: Pale red solid


¹H NMR (600 MHz, CDCl₃): δ 7.11 – 7.06 (m, 2H), 6.87 – 6.83 (m, 2H), 6.79 (d, *J* = 8.1 Hz, 1H), 6.72 (dd, *J* = 8.1, 2.0 Hz, 1H), 6.65 (d, *J* = 2.0 Hz, 1H), 3.88 – 3.85 (m, 4H), 3.86 (s, 3H), 3.83 (s, 3H), 3.15 – 3.10 (m, 4H), 2.86 – 2.81 (m, 4H).

¹³C NMR (151 MHz, CDCl₃): δ 149.7, 148.8, 147.3, 134.7, 133.6, 129.3, 120.4, 116.0, 112.0, 111.3, 67.1, 56.1, 55.9, 49.9, 37.8, 37.4.

HRMS (ESI-TOF): calculated for C₂₀H₂₅NO₃ [M+H]⁺: 328.1913 found: 328.1912.

TLC: R_f = 0.40 (2:1 hexanes/ethyl acetate)

Compound 10



Following the General Procedure 2 with **55** (110.10 mg, 0.4 mmol) and 3-bromo-5-chloropyridine (115.5 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 44 mg (56%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes:ethyl acetate).

Physical State: Clear colorless oil


¹H NMR (500 MHz, CDCl₃): δ 8.44 (d, *J* = 2.3 Hz, 1H), 8.38 (d, *J* = 1.9 Hz, 1H), 7.55 – 7.50 (m, 1H), 4.13 – 4.06 (m, 2H), 3.53 (td, *J* = 11.2, 3.9 Hz, 2H), 2.81 (tt, *J* = 10.7, 5.9 Hz, 1H), 1.87 – 1.76 (m, 4H).

¹³C NMR (151 MHz, CDCl₃): δ 146.9, 146.8, 142.4, 134.1, 132.2, 68.1, 38.9, 33.5.

HRMS (ESI-TOF): calculated for C₁₀H₁₂ClNO [M+H]⁺: 198.0686, found: 198.0684.


TLC: R_f = 0.33 (1:1 hexanes/ethyl acetate)

Compound 11



Following the General Procedure 2 with **S7** (149.8 mg, 0.4 mmol) and 5-iodo-2-chloropyridine (143.7 mg, 0.6 mmol) or 5-bromo-2-chloropyridine (115.5 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 72.3 mg (61%) and 61.6 mg (52%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes:ethyl acetate). The spectroscopic data matched the literature.³⁸

Compound 12



Following the General Procedure 2 with **S8** (123.0 mg, 0.4 mmol) and *N*-(4-bromopyridin-2-yl)acetamide (129.0 mg, 0.6 mmol) in NMP (3 mL) for 3.0 F/mol afforded 58.0 mg (38%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 5:1 to 2:1).

Physical State: White solid


¹H NMR (500 MHz, CDCl₃): δ 9.03 (br, 1H), 8.04 (d, *J* = 5.4 Hz, 1H), 7.98 (s, 1H), 7.32 (m, 4H), 7.32 – 7.22 (m, 1H), 6.70 (dd, *J* = 5.4, 1.8 Hz, 1H), 2.15 (s, 3H), 1.44 – 1.35 (m, 4H).

¹³C NMR (126 MHz, CDCl₃): δ 169.02, 158.58, 152.10, 147.15, 143.35, 129.87, 128.74, 128.71, 127.07, 119.22, 111.93, 29.83, 24.81, 17.66.

HRMS (ESI-TOF): calculated for C₁₆H₁₆N₂O, [M+H]⁺: 253.1341, found: 253.1346.

TLC: R_f = 0.20 (1:1 hexanes/ethyl acetate)

Compound 13



Following the General Procedure 2 with **S9** (123.7 mg, 0.4 mmol) and 2-iodo-3-methoxypyridine (141.0 mg, 0.6 mmol) or 2-bromo-3-methoxypyridine (112.8 mg, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 27.5 mg (30%) and 17.8 mg (20%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes:ethyl acetate).

Physical State: White solid

¹H NMR (600 MHz, CDCl₃): δ 8.14 (t, *J* = 3.0 Hz, 1H), 7.11 (d, *J* = 3.1 Hz, 2H), 3.84 (s, 3H), 3.23 – 3.15 (m, 1H), 2.27 – 2.15 (m, 2H), 2.06 – 1.95 (m, 2H), 1.94 – 1.78 (m, 4H).

¹³C NMR (151 MHz, CDCl₃): δ 153.6, 153.0, 140.7, 122.0, 116.9, 55.3, 37.3, 34.2, 34.0, 34.0, 33.9, 27.4, 27.3.

¹⁹F NMR (471 MHz, CDCl₃): δ -91.44 (d, *J* = 234.6 Hz), -101.64 (d, *J* = 234.4 Hz).

HRMS (ESI-TOF): calculated for C₁₂H₁₅F₂NO [M+H]⁺: 228.1200, found. 228.1205.

TLC: R_f = 0.71 (1:1 hexanes/ethyl acetate)

Compound 14



Following the General Procedure 2 with **S10** (144.2 mg, 0.4 mmol) and 2-iodopyridine (64 μL , 0.6 mmol) or 2-bromopyridine (57 μL , 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 46.6 mg (47%) and 51.8 mg (52%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

Physical State: Clear colorless oil

^1H NMR (600 MHz, CDCl_3): δ 8.54 (d, $J = 5.1$ Hz, 1H), 7.61 (t, $J = 7.9$ Hz, 1H), 7.20 – 7.09 (m, 2H), 3.88 – 3.74 (m, 1H), 3.68 – 3.32 (m, 4H), 2.31 – 2.08 (m, 2H), 1.45 (d, $J = 7.6$ Hz, 9H).


^{13}C NMR (151 MHz, CDCl_3): *Major Rotamer* δ 160.9, 154.7, 149.6, 136.7, 122.0, 121.9, 79.3, 51.4, 46.3, 45.8, 31.6, 28.7.

Minor Rotamer: δ 161.1, 154.7, 149.6, 136.7, 122.0, 121.9, 79.3, 51.1, 46.1, 45.5, 32.3, 28.7.

HRMS (ESI-TOF): calculated for $\text{C}_{14}\text{H}_{20}\text{N}_2\text{O}_2$ $[\text{M}-\text{Boc}+2\text{H}]^+$: 149.1079, found: 149.1077.


TLC: $R_f = 0.43$ (1:1 ethyl acetate/hexanes)

Compound 15



Following the General Procedure 2 with **S11** (144.2 mg, 0.4 mmol) and 2-iodonicotinonitrile (138.0 mg, 0.6 mmol) or 2-bromonicotinonitrile (109.8 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 41.1 mg (38%) and 33.9 mg (31%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 10:1 to 6:1). The spectroscopic data matched the literature.³⁹

Compound 16



Following the General Procedure 2 with **42** (115.0 mg, 0.4 mmol) and 5-bromo-2-iodopyrimidine (171.0 mg, 0.6 mmol) in DMF (3 mL) for 4.0 F/mol afforded 44.5 mg (44%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 5:1 to 3:1).

Physical State: White solid


¹H NMR (500 MHz, CDCl₃): δ 8.73 (s, 2H), 3.33 (tt, *J* = 10.7, 3.7 Hz, 1H), 2.57 – 2.42 (m, 4H), 2.37 – 2.29 (m, 2H), 2.21 – 2.09 (m, 2H).

¹³C NMR (126 MHz, CDCl₃): δ 210.88, 170.62, 157.91, 118.36, 44.34, 40.55, 31.35.

HRMS (ESI-TOF): calculated for C₁₀H₁₁BrN₂O, [M+H]⁺: 255.0133, found: 255.0137.

TLC: R_f = 0.38 (2:1 hexanes/ethyl acetate)

Compound 17



Following the General Procedure 2 with **S12** (151.4 mg, 0.4 mmol) and 2-chloro-5-iodopyrimidine (144.3 mg, 0.6 mmol) in DMF (3 mL) for 2.5 F/mol afforded 30.3 mg (25%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

Physical State: Clear colorless oil

¹H NMR (600 MHz, MeOD): δ 8.71 (s, 2H), 5.25 (br s, 1H), 4.64 (br s, 2H), 3.57 (s, 1H), 3.00 (br s, 1H), 1.57 – 1.09 (br m, 9H).

¹³C NMR (151 MHz, MeOD): δ 161.4, 159.4, 159.4, 159.4, 154.8, 82.7, 60.3, 60.3, 28.5.

HRMS (ESI-TOF): calculated for C₁₂H₁₆ClN₃O₂S [M+H]⁺: 302.0730, found 302.0728.

TLC: R_f = 0.71 (50% ethyl acetate/hexanes)

Compound 18



Following the General Procedure 2 with **S13** (166.0 mg, 0.4 mmol) and 4-bromopyrimidine (95.0 mg, 0.6 mmol) in NMP (3 mL) for 3.0 F/mol afforded 79.6 mg (65%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 2:1 to 1:3).

Physical State: White solid


¹H NMR (500 MHz, CDCl₃): δ 9.07 (s, 1H), 8.53 (s, 2H), 4.54 (br, 1H), 3.03 (d, *J* = 6.5 Hz, 2H), 2.56 (s, 2H), 1.52 (hept, *J* = 7.5 Hz, 4H), 1.45 (s, 9H), 1.33 (dt, *J* = 11.7, 5.2 Hz, 4H), 1.21 (ddd, *J* = 13.5, 8.0, 5.1 Hz, 2H).

¹³C NMR (126 MHz, CDCl₃): δ 158.34, 157.07, 156.32, 131.60, 79.70, 45.96, 37.80, 37.68, 32.77, 28.56, 25.96, 21.58.

HRMS (ESI-TOF): calculated for C₁₇H₂₇N₃O₂, [M+H]⁺: 306.2182, found: 306.2190.

TLC: R_f = 0.42 (1:2 hexanes/ethyl acetate)

Compound 19



Following the General Procedure 2 with **S14** (109.0 mg, 0.4 mmol) and ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (140.0 mg, 0.6 mmol) in DMF (3 mL) for 4.0 F/mol afforded 68.4 mg (61%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 20:1 to 15:1).

Physical State: White solid


¹H NMR (500 MHz, CDCl₃): δ 8.88 (s, 1H), 5.82 – 5.70 (m, 2H), 4.36 (q, *J* = 7.1 Hz, 2H), 3.82 (ddt, *J* = 10.8, 7.9, 4.9 Hz, 1H), 2.58 (s, 3H), 2.55 – 2.43 (m, 1H), 2.27 – 2.10 (m, 3H), 1.91 – 1.85 (m, 2H), 1.38 (t, *J* = 7.1 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 175.50, 175.17, 165.31, 159.15, 126.69, 126.43, 118.33, 61.57, 38.72, 30.12, 28.24, 25.72, 14.47, 14.38.

HRMS (ESI-TOF): calculated for C₁₄H₁₈N₂O₂S, [M+H]⁺: 279.1167, found: 279.1171.

TLC: R_f = 0.45 (10:1 hexanes/ethyl acetate)

Compound 20



Following the General Procedure 2 with **S15** (144.0 mg, 0.4 mmol) and methyl 5-chloropyrazine-2-carboxylate (103.5 mg, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 62.3 mg (51%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 2:1 to 1:3).

Physical State: pale yellow solid


¹H NMR (500 MHz, CDCl₃): ¹H NMR (500 MHz, CDCl₃) δ 9.20 (d, *J* = 1.5 Hz, 1H), 8.54 (d, *J* = 1.5 Hz, 1H), 4.06 (t, *J* = 8.4 Hz, 2H), 4.02 (s, 3H), 3.70 (dd, *J* = 8.8, 5.4 Hz, 2H), 3.20 (d, *J* = 7.8 Hz, 2H), 3.04 (pt, *J* = 8.0, 5.4 Hz, 1H), 1.42 (s, 9H).

¹³C NMR (126 MHz, CDCl₃): δ 164.65, 158.77, 156.47, 145.81, 143.99, 141.34, 79.66, 54.30 (br, low intensity), 53.22, 39.62, 28.54, 28.06.

HRMS (ESI-TOF): calculated for C₁₅H₂₁N₃O₄, [M+H]⁺: 308.1610, found: 308.1613.

TLC: R_f = 0.37 (1:2 hexanes/ethyl acetate)

Compound 21



Following the General Procedure 2 with **S16** (155.0 mg, 0.4 mmol) and methyl 5-chloropyridazine-3-carboxylate (103.5 mg, 0.6 mmol) in DMF (3 mL) for 4.0 F/mol afforded 55.6 mg (41%) of the title compound after purification by column chromatography (gradient elution dichloromethane/methanol from 100:1 to 20:1).

Physical State: pale yellow solid


¹H NMR (500 MHz, CDCl₃): δ 8.09 (d, *J* = 8.6 Hz, 1H), 7.41 (d, *J* = 8.6 Hz, 1H), 4.08 (m, *J* = 5.5 Hz, 1H), 4.06 (s, 3H), 2.99 (d, *J* = 7.2 Hz, 2H), 2.66 (m, 2H), 2.06 (ddq, *J* = 11.5, 7.7, 3.8 Hz, 1H), 1.61 (d, *J* = 13.2 Hz, 2H), 1.44 (s, 9H), 1.24 (qd, *J* = 12.4, 4.4 Hz, 2H).

¹³C NMR (126 MHz, CDCl₃): δ 164.96, 164.55, 154.96, 150.09, 127.60, 127.49, 79.58, 53.40, 43.81(br, low intensity), 43.20, 36.82, 31.98, 28.61.

HRMS (ESI-TOF): calculated for C₁₇H₂₅N₃O₄ [M-Boc+2H]⁺: 236.1399, found: 236.1403.


TLC: R_f = 0.33 (2:1 dichloromethane/methanol)

Compound 22



Following the General Procedure 2 with **S17** (103.7 mg, 0.4 mmol) and 5-iodouracil (142.8 mg, 0.6 mmol) or 5-bromouracil (142.8 mg, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 30.3 mg (42%) and 15.9 mg (22%) respectively of the title compound after purification by column chromatography (ethyl acetate). The spectroscopic data matched the literature.⁴⁰

Compound 23



Following the General Procedure 2 with **S18** (126.1 mg, 0.4 mmol) and tert-butyl 4-iodo-1H-imidazole-1-carboxylate (176.5 mg, 0.6 mmol) or tert-butyl 4-bromo-1H-imidazole-1-carboxylate (148.3 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 37.4 mg (32%) and 18.7 mg (16%) respectively of the title compound after purification by column chromatography (hexanes/ethyl acetate 1:1).

Physical State: White solid


¹H NMR (600 MHz, CDCl₃): δ 7.98 (d, *J* = 1.3 Hz, 1H), 7.12 (d, *J* = 1.3 Hz, 1H), 3.70 (s, 3H), 2.34 (s, 6H), 1.61 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 170.6, 147.1, 142.1, 137.1, 113.5, 85.8, 53.6, 51.8, 38.5, 36.3, 28.0.

HRMS (ESI-TOF): calculated for C₁₅H₂₀N₂O₄ [M-Boc+2H]⁺: 193.0977 found: 193.0983.

TLC: R_f = 0.55 (1:1 hexanes/ethyl acetate)

Compound 24



Following the General Procedure 2 with **S19** (103.7 mg, 0.4 mmol) and 4-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (194.4 mg, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 21.7 mg (20%) of the title compound after purification by column chromatography (hexanes/ethyl acetate 25:1).

Physical State: Colorless oil.


¹H NMR (600 MHz, CDCl₃): δ 7.39 (s, 1H), 7.33 (s, 1H), 5.75 (ddt, *J* = 17.1, 10.3, 7.0 Hz, 1H), 5.36 (s, 2H), 5.04 – 4.97 (m, 2H), 3.55 – 3.50 (m, 2H), 2.79 (h, *J* = 6.9 Hz, 1H), 2.32 (dt, *J* = 13.6, 6.7, 1.4 Hz, 1H), 2.23 (dt, *J* = 14.0, 7.2, 1.2 Hz, 1H), 1.22 (d, *J* = 7.0 Hz, 3H), 0.90 – 0.86 (m, 2H), –0.03 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 138.6, 137.0, 128.6, 126.7, 116.4, 80.3, 66.6, 42.7, 29.7, 21.3, 17.9, –1.30.

HRMS (ESI-TOF): calculated for C₁₄H₂₆N₂OSi [M+H]⁺: 267.1893 found: 267.1895.

TLC: R_f = 0.80 (2:1 hexanes/ethyl acetate)

Compound 25



Following the General Procedure 2 with **S20** (133.7 mg, 0.4 mmol) and 4-iodo-2-methylthiazole (135.0 mg, 0.6 mmol) or 4-bromo-2-methylthiazole (106.8 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 34.9 mg (36%) and 19.0 mg (20%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 10:1 to 4:1).

Physical State: Colorless oil


¹H NMR (600 MHz, CDCl₃): δ 6.97 (s, 1H), 4.91 (br s, 1H), 3.46 (q, *J* = 6.5 Hz, 2H), 2.90 (t, *J* = 6.7 Hz, 2H), 2.69 (s, 3H), 1.43 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 166.0, 156.0, 154.1, 113.8, 79.3, 40.1, 31.8, 28.6, 19.3.

HRMS (ESI-TOF): calculated for C₁₁H₁₈N₂O₂S [M+H]⁺: 243.1167 found: 243.1166.

TLC: R_f = 0.24 (1:1 hexanes/ethyl acetate)

Compound 26



Following the General Procedure 2 with **S21** (107.0 mg, 0.4 mmol) and 2,4-dibromothiazole (146.0 mg, 0.6 mmol) in DMF (3 mL) for 3.5 F/mol afforded 47.5 mg (49%) of the title compound after purification by column chromatography (hexanes/ethyl acetate 50:1).

Physical State: Colorless oil


¹H NMR (500 MHz, CDCl₃): δ 7.10 (s, 1H), 3.62 (t, *J* = 6.3 Hz, 2H), 3.20 – 3.16 (m, 2H), 2.30 – 2.25 (m, 2H).

¹³C NMR (126 MHz, CDCl₃): δ 170.51, 124.74, 116.26, 43.79, 32.10, 30.64.

HRMS (ESI-TOF): calculated for C₆H₇BrClNS, [M+H]⁺: 239.9249, found: 239.9259.

TLC: R_f = 0.38 (10:1 hexanes/ethyl acetate)

Compound 27



Following the General Procedure 2 with **S22** (215.1 mg, 0.4 mmol) and 3-iodothiophene (61 μ L, 0.6 mmol) or 3-bromothiophene (56 μ L, 0.6 mmol) in DMF (3 mL) for 3.5 F/mol afforded 99.2 mg (58%) with the iodide and 6% NMR yield with the bromide of the title compound after purification of the iodide coupling reaction mixture by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).


Physical State: White foamy solid

^1H NMR (500 MHz, CDCl_3): δ 7.23 (dd, $J = 4.9, 2.9$ Hz, 1H), 6.93 (dd, $J = 4.9, 1.3$ Hz, 1H), 6.91 (dt, $J = 3.0, 1.1$ Hz, 1H), 3.85 (d, $J = 3.1$ Hz, 1H), 3.50 – 3.43 (m, 1H), 2.69 (ddd, $J = 15.2, 11.0, 4.7$ Hz, 1H), 2.51 (ddd, $J = 14.5, 10.8, 6.1$ Hz, 1H), 2.25 – 2.15 (m, 1H), 2.02 – 1.95 (m, 2H), 1.91 (dtd, $J = 12.9, 9.4, 6.2$ Hz, 1H), 1.83 (td, $J = 12.1, 4.1$ Hz, 2H), 1.78 – 1.66 (m, 3H), 1.63 (ddt, $J = 12.3, 9.5, 4.9$ Hz, 2H), 1.54 – 1.42 (m, 4H), 1.42 – 1.23 (m, 7H), 1.23 – 1.18 (m, 2H), 1.18 – 1.07 (m, 1H), 1.02 – 0.97 (m, 1H), 1.00 (d, $J = 6.5$ Hz, 3H), 0.91 (s, 3H), 0.66 (s, 3H).

^{13}C NMR (151 MHz, CDCl_3): δ 143.7, 128.5, 125.2, 119.7, 72.2, 68.7, 56.0, 50.6, 42.9, 41.6, 40.0, 39.8, 39.6, 37.0, 35.7, 35.5, 35.2, 34.7, 33.0, 30.8, 28.4, 27.0, 23.9, 22.9, 20.7, 18.7, 11.9

TLC: $R_f = 0.35$ (1:1 ethyl acetate/hexanes)

Compound 28



Following the General Procedure 2 with **S23** (123.7 mg, 0.4 mmol) and 5-iodo-1*H*-indole (145.8 mg, 0.6 mmol) or 5-bromo-1*H*-indole (117.6, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 57.3 mg (61%) and 31.0 mg (33%) respectively of the title compound after purification of the iodide coupling reaction mixture by column chromatography (hexanes/ethyl acetate 9:1).

Physical State: Colorless Oil


¹H NMR (600 MHz, CDCl₃): δ 8.07 (s, 1H), 7.32 (dt, *J* = 8.3, 0.9 Hz, 1H), 7.23 (dd, *J* = 8.2, 6.8 Hz, 2H), 7.19 (dd, *J* = 3.1, 2.4 Hz, 1H), 7.18 – 7.14 (m, 1H), 7.14 – 7.11 (m, 2H), 7.07 (dd, *J* = 8.4, 1.7 Hz, 1H), 6.50 (ddd, *J* = 3.0, 2.0, 1.0 Hz, 1H), 3.10 (dq, *J* = 8.6, 6.7 Hz, 1H), 3.03 (dd, *J* = 13.3, 6.2 Hz, 1H), 2.80 (dd, *J* = 13.3, 8.6 Hz, 1H), 1.28 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (151 MHz, CDCl₃): δ 141.5, 138.9, 134.6, 129.3, 128.2, 128.1, 125.8, 124.4, 121.9, 118.5, 110.9, 102.6, 45.8, 42.0, 21.9.

HRMS (ESI-TOF): calculated for C₁₇H₁₇N [M+H]⁺: 236.1439 found: 236.1447.

TLC: R_f = 0.45 (4:1 hexanes/ethyl acetate)

Compound 29



Following the General Procedure 2 with **S24** (102.9 mg, 0.4 mmol) and 3-iodo-1,5-naphthyridine (153.0 mg, 0.6 mmol) or 3-bromo-1,5-naphthyridine (124.8, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 33.9 mg (43%) and 9.1 mg (12%) respectively of the title compound after purification of the iodide coupling reaction mixture by column chromatography (gradient elution, hexanes/ethyl acetate from 10:1 to 6:1).

Physical State: Colorless oil


¹H NMR (600 MHz, CDCl₃): δ 8.80 (d, *J* = 2.3 Hz, 1H), 8.08 (d, *J* = 8.5 Hz, 1H), 7.95 (s, 1H), 7.77 (d, *J* = 8.2 Hz, 1H), 7.66 (ddd, *J* = 8.3, 6.8, 1.4 Hz, 1H), 7.53 (ddd, *J* = 8.1, 6.8, 1.2 Hz, 1H), 2.94 (t, *J* = 7.7 Hz, 2H), 2.27 (td, *J* = 6.9, 2.6 Hz, 2H), 2.04 (t, *J* = .6 Hz, 1H), 1.98 – 1.92 (m, 2H).

¹³C NMR (151 MHz, CDCl₃): δ 152.1, 147.1, 134.6, 134.2, 129.3, 128.9, 128.2, 127.5, 126.8, 83.7, 69.4, 32.0, 29.7, 17.9.

HRMS (ESI-TOF): calculated for C₁₄H₁₃N [M+H]⁺: 196.1126 found: 196.1127.


TLC: R_f = 0.52 (2:1 hexanes/ethyl acetate)

Compound 30



Following the General Procedure 2 with **S25** (138.0 mg, 0.4 mmol) and 6-bromopyrazolo[1,5-a]pyrimidine (119.0 mg, 0.6 mmol) in NMP (3 mL) for 3.5 F/mol afforded 34.1 mg (31%) of the title compound after purification by preparative TLC (dichloromethane/methanol 70:1). The spectroscopic data matched the literature.⁴¹

Compound 31



Following the General Procedure 2 with **S26** (103.7 mg, 0.4 mmol) and 5-bromo-1-(phenylsulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridine (202.3 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 44.6 mg (34%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

Physical State: Clear colorless oil


¹H NMR (500 MHz, CDCl₃): δ 8.39 (d, *J* = 2.2 Hz, 1H), 8.22 – 8.17 (m, 2H), 7.79 – 7.77 (m, 1H), 7.75 (d, *J* = 4.0 Hz, 1H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.49 (t, *J* = 7.7 Hz, 2H), 6.58 (dd, *J* = 4.1, 0.8 Hz, 1H), 3.78 (p, *J* = 8.1 Hz, 1H), 3.62 – 3.51 (m, 2H), 3.30 – 3.20 (m, 2H).

¹³C NMR (151 MHz, CDCl₃): δ 205.6, 146.4, 144.3, 138.5, 134.5, 134.2, 129.2, 128.2, 127.4, 127.1, 123.0, 105.3, 55.2, 26.4.

HRMS (ESI-TOF): calculated for C₁₇H₁₄N₂O₃S [M+H]⁺: 327.0803, found: 327.0806.


TLC: R_f = 0.16 (3:1 hexanes/ethyl acetate)

Compound 32



Following the General Procedure 3 with tetrahydro-2*H*-pyran-4-carboxylic acid (52.1 mg, 0.4 mmol) and 4-bromobenzonitrile (109.2 mg, 0.6 mmol) in NMP for the electrochemical coupling (2.5 mL) for 2.5 F/mol afforded 46.6 mg (62%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 76% using 1,3,5-trimethoxybenzene as an internal standard. The spectroscopic data matched the literature.⁴²

Compound 33



Following the General Procedure 3 with 4,4,4-trifluorobutanoic acid (56.8 mg, 0.4 mmol) and methyl 5-iodo-2-methylnicotinate (166.2 mg, 0.6 mmol) in NMP for the electrochemical coupling (2.5 mL) for 2.5 F/mol afforded 32.7 mg (33%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 10:1 to 6:1). NMR yield before isolation: 53% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: Colorless oil

¹H NMR (600 MHz, CDCl₃): δ 8.48 (d, *J* = 2.3 Hz, 1H), 8.04 (d, *J* = 2.4 Hz, 1H), 3.93 (s, 3H), 2.92 – 2.89 (m, 2H), 2.81 (s, 3H), 2.46 – 2.36 (m, 2H).


¹³C NMR (151 MHz, CDCl₃): δ 166.9, 158.5, 151.8, 138.2, 131.7, 127.4, 125.3, 52.2, 35.2 (q, *J* = 28.8 Hz), 25.0 (q, *J* = 23.3 Hz), 24.5.

¹⁹F NMR (376 MHz, CDCl₃): δ 69.14.

HRMS (ESI-TOF): calculated for C₁₁H₁₂F₃NO₂ [M+H]⁺: 248.0898 found: 248.0906.

TLC: R_f = 0.46 (2:1 hexanes/ethyl acetate)

Compound 34



Following the General Procedure 3 with 3-oxabicyclo[3.1.1]heptane-1-carboxylic acid (56.8 mg, 0.4 mmol) and methyl 4-bromo-2-fluoropyridine (105.0 mg, 0.6 mmol) in DMF for the electrochemical coupling (2.5 mL) for 4.0 F/mol afforded 26.4 mg (34%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 8:1 to 5:1). NMR yield before isolation: 34% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: Colorless liquid

^1H NMR (500 MHz, CDCl_3): δ 8.13 (d, $J = 5.2$ Hz, 1H), 6.91 – 6.89 (m, 1H), 6.66 – 6.61 (m, 1H), 4.01 (d, $J = 2.1$ Hz, 2H), 3.89 (s, 2H), 2.49 – 2.42 (m, 1H), 2.24 (td, $J = 6.4, 2.6$ Hz, 2H), 2.09 (dd, $J = 6.3, 2.7$ Hz, 2H).


^{13}C NMR (126 MHz, CDCl_3): δ 164.21 (d, $^1J_{CF} = 238.9$ Hz), 160.01 (d, $^3J_{CF} = 7.6$ Hz), 147.84 (d, $J = 15.3$ Hz), 118.68 (d, $J_{CF} = 4.3$ Hz), 106.57 (d, $^2J_{CF} = 37.2$ Hz), 75.61, 70.31, 46.95 (d, $J_{CF} = 2.9$ Hz), 35.46, 31.16.

^{19}F NMR (376 MHz, CDCl_3): δ -70.61.

HRMS (ESI-TOF): calculated for $\text{C}_{11}\text{H}_{12}\text{FNO}$, $[\text{M}+\text{H}]^+$: 194.0981, found: 194.0983.

TLC: $R_f = 0.45$ (4:1 hexanes/ethyl acetate)

Compound 35



Following the General Procedure 3 with tetrahydro-2*H*-thiopyran-4-carboxylic acid 1,1-dioxide (71.3 mg, 0.4 mmol) and methyl 4-bromo-1-methyl-1*H*-pyrrolo[2,3-*b*]pyridine-3-carboxylate (161.5 mg, 0.6 mmol) in NMP for the electrochemical coupling (2.5 mL) for 2.5 F/mol afforded 55.3 mg (43%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 2:1 to 1:2). NMR yield before isolation: 52% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: Colorless solid


¹H NMR (600 MHz, CDCl₃): δ 8.36 (d, *J* = 5.0 Hz, 1H), 8.02 (s, 1H), 7.10 (d, *J* = 5.0 Hz, 1H), 4.53 (tt, *J* = 11.9, 3.1 Hz, 1H), 3.92 (s, 3H), 3.85 (s, 3H), 3.40 (td, *J* = 13.9, 3.9 Hz, 2H), 3.20 – 3.13 (m, 2H), 2.43 – 2.36 (m, 2H), 2.36 – 2.29 (m, 2H).

¹³C NMR (151 MHz, CDCl₃): δ 164.7, 148.8, 147.6, 144.7, 137.2, 117.2, 114.8, 105.5, 51.9, 51.6, 38.1, 32.2, 31.0.

HRMS (ESI-TOF): calculated for C₁₅H₁₈N₂O₄S [M+H]⁺: 323.1066 found: 323.1065.

TLC: R_f = 0.27 (1:2 hexanes/ethyl acetate)

Compound 36



Following the General Procedure 3 with (*tert*-butoxycarbonyl)-*L*-tryptophan (121.7 mg, 0.4 mmol) and 3-iodopyridine (123.0 mg, 0.6 mmol) in NMP for the electrochemical coupling (2.5 mL) for 2.5 F/mol afforded 42.0 mg (31%) of the title compound after purification by column chromatography (gradient elution, dichloromethane to 20:1 dichloromethane/methanol). NMR yield before isolation: 46% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: White foamy solid.


¹H NMR (600 MHz, CD₃OD): δ 8.35 (br s, 1H), 8.34 (br s, 1H), 7.72 (d, *J* = 7.9 Hz, 1H), 7.47 (d, *J* = 7.9 Hz, 1H), 7.34 (br s, 1H), 7.31 (t, *J* = 8.8 Hz, 1H), 7.08 (t, *J* = 7.5 Hz, 1H), 6.99 (t, *J* = 7.5 Hz, 1H), 6.91 (s, 1H), 4.96 (t, *J* = 7.7 Hz, 1H), 3.25 (dd, *J* = 14.4, 7.3 Hz, 1H), 3.12 (dd, *J* = 14.4, 7.8 Hz, 1H), 1.39 (s, 9H).

¹³C NMR (151 MHz, CD₃OD): δ 157.7, 148.6, 148.3, 141.3, 138.0, 136.4, 128.7, 125.0, 124.4, 122.3, 119.8, 119.2, 112.3, 111.6, 80.4, 55.1, 33.8, 28.7.

HRMS (ESI-TOF): calculated for C₂₀H₂₃N₃O₂ [M+H]⁺: 338.1869, found: 338.1872.

TLC: R_f = 0.08 (diethyl ether)

Compound 37



Following the General Procedure 3 with (*tert*-butoxycarbonyl)glycyl-*D*-tyrosine (135.4 mg, 0.4 mmol) and methyl 4-iodobenzoate (157.3 mg, 0.6 mmol) in NMP for the electrochemical coupling (2.5 mL) for 2.5 F/mol afforded 68.8 mg (40%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 45% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: Clear amorphous solid.


¹H NMR (600 MHz, CD₃OD): δ 7.93 (d, *J* = 8.0 Hz, 2H), 7.36 (d, *J* = 8.0 Hz, 2H), 6.91 (d, *J* = 8.0 Hz, 2H), 6.69 – 6.58 (m, 2H), 5.14 (t, *J* = 7.4 Hz, 1H), 3.89 (s, 3H), 3.72 – 3.56 (m, 2H), 3.02 – 2.93 (m, 2H), 1.44 (s, 9H).

¹³C NMR (151 MHz, CD₃OD): δ 171.8, 168.4, 158.4, 157.2, 149.1, 131.3, 130.5, 130.1, 129.4, 128.0, 116.1, 80.8, 56.3, 52.6, 44.6, 42.5, 28.7.

HRMS (ESI-TOF): calculated for C₂₃H₂₈N₂O₆ [M+H]⁺: 429.2026, found: 429.2022.

TLC: R_f = 0.11 (1:1 hexanes/ethyl acetate)

Compound 38



Following the General Procedure 2 with **39** (193.0 mg, 0.4 mmol) and 3-iodopyridine (123.0 mg, 0.6 mmol) or 3-bromopyridine (59 μ L, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 93 mg (63%) and 67 mg (45%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

BATCH SCALE UP PROCEDURE

Following the General Procedure 4 with **39** (2.41 g, 5.0 mmol) and 3-iodopyridine (1.54 mg, 7.5 mmol) or 3-bromopyridine (732 μ L, 7.5 mmol) in NMP (18 mL) for 3.5 F/mol afforded 977 mg (52%) and 745 mg (40%) respectively of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

FLOW

Following the General Procedure 5 with *N*-(*tert*-Butoxycarbonyl)-L-glutamic acid 1-benzyl ester (33.7 g, 100.0 mmol) and 3-iodopyridine (30.8 mg, 150 mmol) in NMP (625 mL) for 4.5 F/mol afforded 18.1 g (49%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate).

Physical State: Pale yellow oil


¹H NMR (600 MHz, CDCl₃): δ 8.44 (d, J = 4.8 Hz, 1H), 8.37 (d, J = 2.3 Hz, 1H), 7.44 – 7.40 (m, 1H), 7.40 – 7.32 (m, 5H), 7.19 (dd, J = 7.8, 4.8 Hz, 1H), 5.21 (d, J = 12.1 Hz, 1H), 5.12 (d, J = 12.3 Hz, 1H), 5.12 (br s, 1H), 4.41 (s, 1H), 2.65 (ddd, J = 14.1, 10.5, 6.1 Hz, 1H), 2.57 (td, J = 12.5, 5.6 Hz, 1H), 2.21 – 2.08 (m, 1H), 1.94 (dddd, J = 13.5, 10.6, 7.6, 5.6 Hz, 1H), 1.45 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 172.3, 155.4, 150.0, 147.9, 136.2, 136.0, 135.4, 128.8, 128.8, 128.6, 123.5, 80.3, 67.4, 53.3, 34.3, 28.8, 28.5.

HRMS (ESI-TOF): calculated for C₂₁H₂₆N₂O₄ [M+H]⁺: 371.1971, found: 371.1962.


TLC: R_f = 0.20 (1:1 hexanes/ethyl acetate)

Compound 40



Following the General Procedure 2 with **42** (114.9 mg, 0.4 mmol) and 4-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (194.5 mg, 0.6 mmol) in DMF (3 mL) for 4.0 F/mol afforded 37.0 mg (31%) of the title compound after purification by column chromatography (gradient elution, hexanes/ethyl acetate from 4:1 to 1:1). The spectroscopic data matched the literature.⁴³

Compound 44



Following the General Procedure 2 with **47** (114.9 mg, 0.4 mmol) and 5-bromo-2-iodopyrimidine (171.0 mg, 0.6 mmol) in DMF (3 mL) for 4.0 F/mol afforded 38.6 mg (28%) of the title compound after purification by column chromatography (hexanes/ethyl acetate 2:1).

Physical State: White solid


¹H NMR (600 MHz, CDCl₃): δ 8.81 (s, 2H), 4.63 (dd, *J* = 10.7, 2.8 Hz, 1H), 4.34 (d, *J* = 70.8 Hz, 1H), 4.10 (d, *J* = 11.2 Hz, 1H), 3.96 (s, 1H), 3.73 (td, *J* = 11.7, 2.9 Hz, 1H), 3.07 (s, 2H), 1.47 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 164.8, 158.2, 154.7, 119.6, 80.5, 77.9, 67.0, 48.1, 47.1, 44.0, 42.7, 28.5.

HRMS (ESI-TOF): calculated for C₁₃H₁₈BrN₃O₃ [M-Boc+2H]⁺: 244.0080 found: 244.0073.


TLC: R_f = 0.55 (1:1 hexanes/ethyl acetate)

Compound 48



Following the General Procedure 2 with **49** (230.9 mg, 0.4 mmol) and 1-(3-(benzyloxy)propyl)-5-bromoindoline-7-carbonitrile (222.6 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 98.8 mg (37%) of the title compound after purification by column chromatography hexanes/ethyl acetate 4:1). The spectroscopic data matched the literature.²⁷

Compound 51



Following the General Procedure 2 with **49** (114.9 mg, 91 wt/wt%, 0.36 mmol) and 5-bromo-4-cyclopropoxy-2-(methylthio)pyrimidine (156.7 mg, 0.6 mmol) in NMP (3 mL) for 2.5 F/mol afforded 64.3 mg (41%) of the title compound after purification by column chromatography (hexanes/ethyl acetate 3:1).

Physical State: White Solid


¹H NMR (600 MHz, CDCl₃): δ 8.11 (s, 1H), 4.44 (tt, $J = 6.4, 3.1$ Hz, 1H), 3.09 (td, $J = 8.4, 7.6, 4.6$ Hz, 1H), 2.94 – 2.87 (m, 1H), 2.84 – 2.69 (m, 3H), 2.55 (s, 3H), 2.00 (dd, $J = 7.9, 4.8$ Hz, 2H), 1.52 (s, 9H), 0.84 – 0.78 (m, 2H), 0.78 – 0.73 (m, 2H).

¹³C NMR (151 MHz, CDCl₃): δ 169.8, 167.4, 159.0, 154.6, 152.7, 143.9, 120.5, 119.7, 82.5, 51.0, 32.7, 28.4, 28.2, 27.9, 26.0, 14.3, 5.9.

HRMS (ESI-TOF): calculated for C₂₀H₂₆N₄O₃S₂ [M+H]⁺: 435.1525 found: 435.1522.

TLC: R_f = 0.60 (2:1 hexanes/ethyl acetate)

Compound 81



Following the General Procedure 1 (in parallel on carousel with **81** – **86**) with **55** (110.10 mg, 0.4 mmol) and 2-bromo-6-chloro-3-fluoropyridine (126.3 mg, 0.6 mmol) in NMP for the electrochemical coupling (3 mL) for 2.5 F/mol afforded 38.0 mg (44%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 51% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: White solid

¹H NMR (600 MHz, CDCl₃): δ 8.35 (dd, *J* = 2.1, 0.8 Hz, 1H), 7.38 (dd, *J* = 9.4, 2.0 Hz, 1H), 4.09 (ddt, *J* = 11.6, 4.5, 1.1 Hz, 2H), 3.56 (td, *J* = 12.0, 2.1 Hz, 2H), 3.25 (ttd, *J* = 11.8, 3.8, 1.7 Hz, 1H), 2.03 (dtd, *J* = 13.6, 12.0, 4.4 Hz, 2H), 1.83 – 1.66 (m, 2H).


¹³C NMR (151 MHz, CDCl₃): δ 157.4, 155.7, 150.7, 150.6, 144.0, 129.7, 123.3, 123.2, 123.1, 123.1, 68.1, 68.1, 68.0, 68.0, 36.7, 30.8.

¹⁹F NMR (376 MHz, CDCl₃): δ -127.2.

HRMS (ESI-TOF): calculated for C₁₀H₁₁ClFNO [M+H]⁺: 216.0591 found: 216.0598.

TLC: R_f = 0.58 (3:1 hexanes/ethyl acetate)

Compound 82



Following the General Procedure 1 (in parallel on carousel with **81** – **86**) with **55** (110.10 mg, 0.4 mmol) and 2-bromo-5-methoxypyridine (112.8 mg, 0.6 mmol) in NMP for the electrochemical coupling (3 mL) for 2.5 F/mol afforded 24.5 mg (32%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 34% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: Pale yellow oil


¹H NMR (600 MHz, CDCl₃): δ 8.23 (dd, *J* = 3.0, 0.7 Hz, 1H), 7.15 (dd, *J* = 8.6, 3.0 Hz, 1H), 7.08 (d, *J* = 8.6 Hz, 1H), 4.11 – 4.04 (m, 2H), 3.83 (s, 3H), 3.58 – 3.48 (m, 2H), 2.94 – 2.85 (m, 1H), 1.84 (ddt, *J* = 9.1, 5.3, 3.8 Hz, 4H).

¹³C NMR (151 MHz, CDCl₃): δ 162.1, 147.0, 138.0, 130.2, 121.3, 68.4, 39.5, 31.5, 18.7.

HRMS (ESI-TOF): calculated for C₁₁H₁₅NO₂ [M+H]⁺: 194.1181 found: 194.1185.

TLC: R_f = 0.22 (1:1 hexanes/ethyl acetate)

Compound 83



Following the General Procedure 1 (in parallel on carousel with **81** – **86**) with **55** (110.10 mg, 0.4 mmol) and 2-iodo-3-methylpyridine (131.4 mg, 0.6 mmol) in NMP for the electrochemical coupling (3 mL) for 2.5 F/mol afforded 20.2 mg (28%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 28% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: Pale yellow oil


¹H NMR (600 MHz, CDCl₃): δ 8.42 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.41 (ddd, *J* = 7.6, 1.8, 0.9 Hz, 1H), 7.02 (dd, *J* = 7.6, 4.8 Hz, 1H), 4.10 (ddt, *J* = 11.6, 4.6, 1.1 Hz, 2H), 3.56 (ddd, *J* = 12.3, 11.3, 2.0 Hz, 2H), 3.09 (tt, *J* = 11.7, 3.7 Hz, 1H), 2.35 (s, 3H), 2.09 (dddd, *J* = 13.7, 12.3, 11.5, 4.4 Hz, 2H), 1.70 – 1.59 (m, 2H).

¹³C NMR (151 MHz, CDCl₃): δ 162.1, 147.0, 138.0, 130.2, 121.3, 68.4, 39.5, 31.5, 18.7.

HRMS (ESI-TOF): calculated for C₁₁H₁₅NO [M+H]⁺: 178.1232 found: 178.1237.

TLC: R_f = 0.32 (1:1 hexanes/ethyl acetate)

Compound 84



Following the General with Procedure 1 (in parallel on carousel with **81 – 86**) with **S28** (149.8 mg, 0.4 mmol) and methyl 4-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (161.5 mg, 0.6 mmol) in NMP for the electrochemical coupling (3 mL) for 2.5 F/mol afforded 67.8 mg (46%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 57% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: Foamy solid.

¹H NMR (600 MHz, CDCl₃): δ 8.25 (dd, $J = 17.0, 4.8$ Hz, 1H), 7.96 (d, $J = 7.6$ Hz, 1H), 6.96 (d, $J = 4.8$ Hz, 1H), 3.89 (d, $J = 5.7$ Hz, 3H), 3.84 (d, $J = 6.9$ Hz, 3H), 3.55 – 3.25 (m, 4H), 3.20 (qd, $J = 10.6, 7.1$ Hz, 1H), 3.02 (dd, $J = 10.7, 8.4$ Hz, 1H), 2.50 (tt, $J = 15.3, 8.0$ Hz, 1H), 1.84 (dd, $J = 12.9, 7.6$ Hz, 1H), 1.70 – 1.53 (m, 1H), 1.42 (s, 9H).


¹³C NMR (151 MHz, CDCl₃): (1:1 mixture of rotamers) *Rotamer 1* δ 164.4, 154.8, 148.9, 144.9, 144.0, 136.6, 119.8, 117.8, 105.9, 79.0, 51.4, 51.3, 45.8, 40.6, 37.8, 32.1, 31.6, 28.7.

Rotamer 2 δ 164.4, 154.7, 148.9, 144.9, 144.0, 136.6, 119.8, 117.7, 105.9, 79.0, 51.4, 50.8, 45.4, 40.0, 37.6, 32.1, 30.6, 28.6.

HRMS (ESI-TOF): calculated for C₂₀H₂₇N₃O₄ [M+Na]⁺: 396.1603 found: 396.1909.

TLC: R_f = 0.29 (1:1 hexanes/ethyl acetate)

Compound 85



Following the General Procedure 1 (in parallel on carousel with **81** – **86**) with **S36** (104.5 mg, 0.4 mmol) and methyl 4-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (161.5 mg, 0.6 mmol) in NMP for the electrochemical coupling (3 mL) for 2.5 F/mol afforded 39.8 mg (37%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 47% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: clear colorless oil


¹H NMR (600 MHz, CDCl₃): δ 8.26 (d, *J* = 4.9 Hz, 1H), 7.95 (s, 1H), 6.96 (d, *J* = 4.9 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.41 (s, 2H), 0.89 (s, 9H).

¹³C NMR (151 MHz, CDCl₃): δ 164.7, 148.8, 144.9, 143.1, 136.8, 121.7, 119.4, 106.7, 51.4, 45.7, 33.1, 32.1, 29.6.

HRMS (ESI-TOF): calculated for C₁₅H₂₀N₂O₂ [M+H]⁺: 261.1603 found: 261.1610.

TLC: R_f = 0.29 (1:1 hexanes/ethyl acetate)

Compound 86



Following the General Procedure 4 with **S29** (115.7 mg, 0.4 mmol) and methyl 4-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (161.5 mg, 0.6 mmol) in NMP for the electrochemical coupling (3 mL) for 2.5 F/mol afforded 5.0 mg (5%) of the title compound after purification by column chromatography (gradient elution, hexanes to 1:1 hexanes/ethyl acetate). NMR yield before isolation: 11% using 1,3,5-trimethoxybenzene as an internal standard.

Physical State: White amorphous solid


¹H NMR (500 MHz, CDCl₃): δ 8.27 (d, *J* = 5.0 Hz, 1H), 7.98 (s, 1H), 6.73 (d, *J* = 5.0 Hz, 1H), 3.98 – 3.93 (m, 1H), 3.91 (s, 3H), 3.84 (s, 3H), 3.76 (s, 3H), 1.92 (ddd, *J* = 8.3, 5.4, 4.4 Hz, 1H), 1.76 (dt, *J* = 9.6, 5.0 Hz, 1H), 1.52 – 1.42 (m, 1H).

¹³C NMR (151 MHz, CDCl₃): δ 173.6, 164.5, 148.5, 144.4, 144.1, 136.6, 118.6, 113.9, 106.5, 52.1, 52.0, 51.5, 51.5, 32.2, 32.2, 24.9, 24.9, 24.8, 24.7, 16.7, 16.6.

HRMS (ESI-TOF): calculated for C₁₅H₁₆N₂O₄ [M+H]⁺: 289.1188 found: 289.1194.

TLC: R_f = 0.60 (ethyl acetate) Unstable to SiO₂ Cyclopropane opening and decomposition observed.

Compound S34



Following the General Procedure 4 with 1,3-dioxoisindolin-2-yl (*tert*-butoxycarbonyl)alaninate (134 mg, 0.4 mmol) and 4-iodo-2-methylthiazole (135 mg, 0.600 mmol), in NMP for the electrochemical coupling (3 mL) for 5.0 F/mol afforded 33.0 mg (34%) of the title compound after purification by reverse phase HPLC.

Physical State: White amorphous solid


¹H NMR (400 MHz, DMSO): δ 7.19 (d, J = 8.5 Hz, 1H), 7.08 (s, 1H), 4.70 (q, J = 7.6 Hz, 1H), 2.61 (s, 3H), 1.38 (s, 9H), 1.33 (d, J = 7.0 Hz, 3H).

¹³C NMR (101 MHz, DMSO): δ 164.9, 159.0, 154.8, 112.6, 77.7, 46.7, 28.2, 21.1, 18.7

HRMS (ESI-TOF): calculated for C₁₁H₁₈N₂O₂S [M+H]⁺: 243.1162 found: 243.1155.

TLC: R_f = 0.53 (1:1 heptane/ethyl acetate)

Compound S35



Following the General Procedure 4 with 1,3-dioxoisindolin-2-yl (*tert*-butoxycarbonyl) (139.5 mg, 0.44 mmol) and 7-chloro-4-iodoquinoline (195 mg, 0.653 mmol), in NMP for the electrochemical coupling (3 mL) for 4.0 F/mol afforded 56.0 mg (44%) of the title compound after purification by reverse phase HPLC.

Physical State: White amorphous solid

¹H NMR (400 MHz, DMSO): δ 8.89 (d, J = 4.4 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 8.09 (d, J = 2.2 Hz, 1H), 7.67 (dd, J = 9.0, 2.3 Hz, 1H), 7.59 (s, 1H), 7.38 (d, J = 4.5 Hz, 1H), 4.63 (d, J = 6.0 Hz, 2H), 1.41 (s, 9H).

¹³C NMR (101 MHz, DMSO): δ 155.8, 151.7, 148.1, 145.7, 133.9, 128.1, 127.1, 125.8, 124.6, 119.3, 78.3, 40.4, 28.2.

HRMS (ESI-TOF): calculated for C₁₅H₁₇ClN₂O₂ [M+H]⁺: 293.1051 found: 293.1.

TLC: R_f = 0.80 (1:4 heptane/ethyl acetate)

References


1. Hsiao, Y.-T.; Beadle, J.; Pascoe, C.; Annadate, R.; Vederas, J. C., Decarboxylative Radical Addition to Methylideneoxazolidinones for Stereocontrolled Synthesis of Selectively Protected Diamino Diacids. *Org. Lett.* **2021**, *23* (18), 7270-7273.
2. Stadler, S. M.; Göttker-Schnetmann, I.; Mecking, S., Incorporation of Radicals during Ni(II)-Catalyzed Ethylene Insertion Polymerization. *ACS Catal.* **2019**, *9* (4), 2760-2767.
3. Brauer, J.; Quraishi, E.; Kammer, L. M.; Opatz, T., Nickel-Mediated Photoreductive Cross Coupling of Carboxylic Acid Derivatives for Ketone Synthesis**. *Eur. J. Chem.* **2021**, *27* (72), 18168-18174.
4. Tortajada, A.; Duan, Y.; Sahoo, B.; Cong, F.; Toupalas, G.; Sallustrau, A.; Loreau, O.; Audisio, D.; Martin, R., Catalytic Decarboxylation/Carboxylation Platform for Accessing Isotopically Labeled Carboxylic Acids. *ACS Catal.* **2019**, *9* (7), 5897-5901.
5. Xiao, J.; Li, Z.; Montgomery, J., Nickel-Catalyzed Decarboxylative Coupling of Redox-Active Esters with Aliphatic Aldehydes. *J. Am. Chem. Soc.* **2021**, *143* (50), 21234-21240.
6. Wang, G.-Z.; Shang, R.; Fu, Y., Irradiation-Induced Palladium-Catalyzed Decarboxylative Heck Reaction of Aliphatic N-(Acyloxy)phthalimides at Room Temperature. *Org. Lett.* **2018**, *20* (3), 888-891.
7. Zhang, Y.-L.; Yang, L.; Wu, J.; Zhu, C.; Wang, P., Vinyl Sulfonium Salts as the Radical Acceptor for Metal-Free Decarboxylative Alkenylation. *Org. Lett.* **2020**, *22* (19), 7768-7772.
8. Yang, T.; Jiang, Y.; Luo, Y.; Lim, J. J. H.; Lan, Y.; Koh, M. J., Chemoselective Union of Olefins, Organohalides, and Redox-Active Esters Enables Regioselective Alkene Dialkylation. *J. Am. Chem. Soc.* **2020**, *142* (51), 21410-21419.
9. Hu, D.; Wang, L.; Li, P., Decarboxylative Borylation of Aliphatic Esters under Visible-Light Photoredox Conditions. *Org. Lett.* **2017**, *19* (10), 2770-2773.
10. Mao, R.; Frey, A.; Balon, J.; Hu, X., Decarboxylative C(sp³)-N cross-coupling via synergetic photoredox and copper catalysis. *Nat. Catal.* **2018**, *1* (2), 120-126.
11. Li, J.; Siang Tan, S.; Kyne, S. H.; Wai Hong Chan, P., Minisci-Type Alkylation of N-Heteroarenes by N-(Acyloxy)phthalimide Esters Mediated by a Hantzsch Ester And Blue LED Light. *Adv. Synth. Catal.* **2022**, *364* (4), 802-810.
12. Wang, J.; Shang, M.; Lundberg, H.; Feu, K. S.; Hecker, S. J.; Qin, T.; Blackmond, D. G.; Baran, P. S., Cu-Catalyzed Decarboxylative Borylation. *ACS Catal.* **2018**, *8* (10), 9537-9542.
13. Merchant Rohan, R.; Edwards Jacob, T.; Qin, T.; Kruszyk Monika, M.; Bi, C.; Che, G.; Bao, D.-H.; Qiao, W.; Sun, L.; Collins Michael, R.; Fadeyi Olugbeminiyi, O.; Gallego Gary, M.; Mousseau James, J.; Nuhant, P.; Baran Phil, S., Modular radical cross-coupling with sulfones enables access to sp³-rich (fluoro)alkylated scaffolds. *Science* **2018**, *360* (6384), 75-80.
14. Mousseau, J. J.; Perry, M. A.; Bundesmann, M. W.; Chinigo, G. M.; Choi, C.; Gallego, G.; Hicklin, R. W.; Hoy, S.; Limburg, D. C.; Sach, N. W.; Zhang, Y., Automated Nanomole-Scale Reaction Screening toward Benzoate Bioisosteres: A Photocatalyzed Approach to Highly Elaborated Bicyclo[1.1.1]Pentanes. *ACS Catal.* **2022**, *12* (1), 600-606.
15. Kammer, L. M.; Rahman, A.; Opatz, T., A Visible Light-Driven Minisci-Type Reaction with N-Hydroxyphthalimide Esters. *Molecules* **2018**, *23* (4).
16. Tripathi, K. N.; Belal, M.; Singh, R. P., Organo Photoinduced Decarboxylative Alkylation of Coumarins with N-(Acyloxy)phthalimide. *J. Org. Chem.* **2020**, *85* (2), 1193-1201.

17. Zhao, W.; Wurz, R. P.; Peters, J. C.; Fu, G. C., Photoinduced, Copper-Catalyzed Decarboxylative C–N Coupling to Generate Protected Amines: An Alternative to the Curtius Rearrangement. *J. Am. Chem. Soc.* **2017**, *139* (35), 12153-12156.
18. Fawcett, A.; Pradeilles, J.; Wang, Y.; Mutsuga, T.; Myers Eddie, L.; Aggarwal Varinder, K., Photoinduced decarboxylative borylation of carboxylic acids. *Science* **2017**, *357* (6348), 283-286.
19. Yu, L.; Tang, M.-L.; Si, C.-M.; Meng, Z.; Liang, Y.; Han, J.; Sun, X., Zinc-Mediated Decarboxylative Alkylation of Gem-difluoroalkenes. *Org. Lett.* **2018**, *20* (15), 4579-4583.
20. Tlahuext-Aca, A.; Garza-Sanchez, R. A.; Schäfer, M.; Glorius, F., Visible-Light-Mediated Synthesis of Ketones by the Oxidative Alkylation of Styrenes. *Org. Lett.* **2018**, *20* (6), 1546-1549.
21. Barton Lisa, M.; Chen, L.; Blackmond Donna, G.; Baran Phil, S., Electrochemical borylation of carboxylic acids. *Proc. Natl Acad. Sci. U.S.A.* **2021**, *118* (34), e2109408118.
22. Chandrachud, P. P.; Wojtas, L.; Lopchuk, J. M., Decarboxylative Amination: Diazirines as Single and Double Electrophilic Nitrogen Transfer Reagents. *J. Am. Chem. Soc.* **2020**, *142* (52), 21743-21750.
23. Polites, V. C.; Badir, S. O.; Keess, S.; Jolit, A.; Molander, G. A., Nickel-Catalyzed Decarboxylative Cross-Coupling of Bicyclo[1.1.1]pentyl Radicals Enabled by Electron Donor–Acceptor Complex Photoactivation. *Org. Lett.* **2021**, *23* (12), 4828-4833.
24. Chan, C.-M.; Xing, Q.; Chow, Y.-C.; Hung, S.-F.; Yu, W.-Y., Photoredox Decarboxylative C(sp³)–N Coupling of α -Diazoacetates with Alkyl N-Hydroxyphthalimide Esters for Diversified Synthesis of Functionalized N-Alkyl Hydrazones. *Org. Lett.* **2019**, *21* (19), 8037-8043.
25. Qin, T.; Cornella, J.; Li, C.; Malins Lara, R.; Edwards Jacob, T.; Kawamura, S.; Maxwell Brad, D.; Eastgate Martin, D.; Baran Phil, S., A general alkyl-alkyl cross-coupling enabled by redox-active esters and alkylzinc reagents. *Science* **2016**, *352* (6287), 801-805.
26. Jin, S.; Haug, G. C.; Nguyen, V. T.; Flores-Hansen, C.; Arman, H. D.; Larionov, O. V., Decarboxylative Phosphine Synthesis: Insights into the Catalytic, Autocatalytic, and Inhibitory Roles of Additives and Intermediates. *ACS Catal.* **2019**, *9* (11), 9764-9774.
27. Chen, T.-G.; Mele, L.; Jentzer, O.; Delbrayelle, D.; Echeverria, P.-G.; Vantourout, J. C.; Baran, P. S., Convergent synthesis of (R)-silodosin via decarboxylative cross-coupling. *Tetrahedron Lett.* **2021**, *79*, 153290.
28. Harwood, S. J.; Palkowitz, M. D.; Gannett, C. N.; Perez, P.; Yao, Z.; Sun, L.; Abruña, H. D.; Anderson, S. L.; Baran, P. S., Modular terpene synthesis enabled by mild electrochemical couplings. *Science* **2022**, *375* (6582), 745-752.
29. Huihui, K. M. M.; Caputo, J. A.; Melchor, Z.; Olivares, A. M.; Spiewak, A. M.; Johnson, K. A.; DiBenedetto, T. A.; Kim, S.; Ackerman, L. K. G.; Weix, D. J., Decarboxylative Cross-Electrophile Coupling of N-Hydroxyphthalimide Esters with Aryl Iodides. *J. Am. Chem. Soc.* **2016**, *138* (15), 5016-5019.
30. Koyanagi, T.; Herath, A.; Chong, A.; Ratnikov, M.; Valiere, A.; Chang, J.; Molteni, V.; Loren, J., One-Pot Electrochemical Nickel-Catalyzed Decarboxylative Sp²–Sp³ Cross-Coupling. *Org. Lett.* **2019**, *21* (3), 816-820.
31. Kammer, L. M.; Badir, S. O.; Hu, R.-M.; Molander, G. A., Photoactive electron donor–acceptor complex platform for Ni-mediated C(sp³)–C(sp²) bond formation. *Chem. Sci.* **2021**, *12* (15), 5450-5457.


32. Brown, G. D.; Batalla, D.; Cavallaro, C.; Perez, H. L.; Wroblewski, S.; Sherwood, T., A Compact, Practical Photoreactor for Multi-Reaction Arrays. *React. Chem. Eng.* **2022**, Advance Article. DIO: <https://doi.org/10.1039/D2RE00062H>
33. Prieto Kullmer Cesar, N.; Kautzky Jacob, A.; Krska Shane, W.; Nowak, T.; Dreher Spencer, D.; MacMillan David, W. C., Accelerating reaction generality and mechanistic insight through additive mapping. *Science* **2022**, *376* (6592), 532-539.
34. Cornella, J.; Edwards, J. T.; Qin, T.; Kawamura, S.; Wang, J.; Pan, C.-M.; Gianatassio, R.; Schmidt, M.; Eastgate, M. D.; Baran, P. S., Practical Ni-Catalyzed Aryl-Alkyl Cross-Coupling of Secondary Redox-Active Esters. *J. Am. Chem. Soc.* **2016**, *138* (7), 2174-2177.
35. Pinchman, J. R.; Hopkins, C. D.; Bunker, K. D.; Huang, P. Q. Methods for Cross Coupling. WO2018039232A1, 2018.
36. Singh, P. P.; Gudup, S.; Ambala, S.; Singh, U.; Dadhwal, S.; Singh, B.; Sawant, S. D.; Vishwakarma, R. A., Iron oxide mediated direct C-H arylation/alkylation at α -position of cyclic aliphatic ethers. *Chem. Commun.* **2011**, *47* (20), 5852-5854.
37. Vara, B. A.; Jouffroy, M.; Molander, G. A., C(sp³)-C(sp²) cross-coupling of alkylsilicates with borylated aryl bromides – an iterative platform to alkylated aryl- and heteroaryl boronates. *Chem. Sci.* **2017**, *8* (1), 530-535.
38. Wang, J.; Qin, T.; Chen, T.-G.; Wimmer, L.; Edwards, J. T.; Cornella, J.; Vokits, B.; Shaw, S. A.; Baran, P. S., Nickel-Catalyzed Cross-Coupling of Redox-Active Esters with Boronic Acids. *Angew. Chem. Int. Ed.* **2016**, *55* (33), 9676-9679.
39. Benischke, A. D.; Knoll, I.; Rérat, A.; Gosmini, C.; Knochel, P., A practical cobalt-catalyzed cross-coupling of benzylic zinc reagents with aryl and heteroaryl bromides or chlorides. *Chem. Commun.* **2016**, *52* (15), 3171-3174.
40. Basnak, I.; Balkan, A.; Coe, P. L.; Walker, R. T., The Synthesis of Some 5-Substituted and 5,6-Disubstituted 2'-Deoxyuridines. *Nucleosides and Nucleotides* **1994**, *13* (1-3), 177-196.
41. Aguirre, A. L.; Loud, N. L.; Johnson, K. A.; Weix, D. J.; Wang, Y., ChemBead Enabled High-Throughput Cross-Electrophile Coupling Reveals a New Complementary Ligand. *Eur. J. Chem.* **2021**, *27* (51), 12981-12986.
42. Watanabe, E.; Chen, Y.; May, O.; Ley, S. V., A Practical Method for Continuous Production of sp³-Rich Compounds from (Hetero)Aryl Halides and Redox-Active Esters. *Eur. J. Chem* **2020**, *26* (1), 186-191.
43. Burch, J. D.; Lau, K.; Barker, J. J.; Brookfield, F.; Chen, Y.; Chen, Y.; Eigenbrot, C.; Ellebrandt, C.; Ismaili, M. H. A.; Johnson, A.; Kordt, D.; MacKinnon, C. H.; McEwan, P. A.; Ortwine, D. F.; Stein, D. B.; Wang, X.; Winkler, D.; Yuen, P.-W.; Zhang, Y.; Zarrin, A. A.; Pei, Z., Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors. *J. Med. Chem.* **2014**, *57* (13), 5714-5727.

NMR Spectra


Compound S5 ¹H-NMR




Compound S5 ¹³C-NMR




Compound S6 ¹H-NMR




Compound S6 ¹³C-NMR




Compound S10 ¹H-NMR




Compound S10 ¹³C-NMR




Compound S12 ¹H-NMR




Compound S12 ¹³C-NMR




Compound S22 ¹H-NMR




Compound S22 ¹³C-NMR




Compound 39 ¹H-NMR




Compound 39 ¹³C-NMR




Compound S27 ¹H-NMR




Compound S27 ¹³C-NMR




Compound S30 ¹³C-NMR




Compound S31 ¹H-NMR




Compound S31 ¹³C-NMR




Compound S32 ¹H-NMR




Compound S32 ¹³C-NMR




Compound S32 ¹⁹F-NMR




Compound S33 ¹H-NMR




Compound S33 ¹³C-NMR




Compound 50 ¹H-NMR




Compound 50 ¹³C-NMR




Compound 56 ¹H-NMR




Compound 56 ¹³C-NMR




Compound 1 ¹H-NMR




Compound 1 ¹³C-NMR




Compound 4 ¹H-NMR




Compound 4 ¹³C-NMR




Compound 7 ¹H-NMR




Compound 7 ¹³C-NMR




Compound 8 ¹H-NMR




Compound 8 ¹³C-NMR




Compound 9 ¹H-NMR




Compound 9 ¹³C-NMR




Compound 10 ¹H-NMR




Compound 10 ¹³C-NMR




Compound 12 ¹H-NMR




Compound 12 ¹³C-NMR




Compound 13 ¹H-NMR




Compound 13 ¹³C-NMR




Compound 13 ¹⁹F-NMR




Compound 14 ¹H-NMR




Compound 14 ¹³C-NMR




Compound 16 ¹H-NMR




Compound 16 ¹³C-NMR




Compound 17 ¹H-NMR




Compound 17 ¹³C-NMR




Compound 18 ¹H-NMR




Compound 18 ¹³C-NMR




Compound 19 ¹H-NMR




Compound 19 ¹³C-NMR




Compound 20 ¹H-NMR




Compound 20 ¹³C-NMR




Compound 21 ¹H-NMR




Compound 21 ¹³C-NMR




Compound 23 ¹H-NMR




Compound 23 ¹³C-NMR




Compound 24 ¹³C-NMR




Compound 25 ¹H-NMR




Compound 25 ¹³C-NMR




Compound 26 ¹H-NMR




Compound 26 ¹³C-NMR




Compound 27 ¹H-NMR




Compound 27 ¹³C-NMR




Compound 28 ¹H-NMR




Compound 28 ¹³C-NMR




Compound 29 ¹H-NMR




Compound 29 ¹³C-NMR




Compound 31 ¹H-NMR




Compound 31 ¹³C-NMR




Compound 33 ¹H-NMR




Compound 33 ¹³C-NMR




Compound 33 ¹⁹F-NMR




Compound 34 ¹H-NMR




Compound 34 ¹³C-NMR




Compound 34 ¹⁹F-NMR




Compound 35 ¹H-NMR




Compound 35 ¹³C-NMR




Compound 36 ¹H-NMR




Compound 36 ¹³C-NMR




Compound 37 ¹H-NMR




Compound 37 ¹³C-NMR




Compound 38 ¹H-NMR




Compound 38 ¹³C-NMR




Compound 44 ¹H-NMR




Compound 44 ¹³C-NMR




Compound 51 ¹H-NMR




Compound 51 ¹³C-NMR




Compound 81 ¹H-NMR




Compound 81 ¹³C-NMR




Compound 81 ¹⁹F-NMR




Compound 82 ¹H-NMR




Compound 82 ¹³C-NMR




Compound 83 ¹H-NMR




Compound 83 ¹³C-NMR




Compound 84 ¹H-NMR




Compound 84 ¹³C-NMR




Compound 85 ¹H-NMR




Compound 85 ¹³C-NMR




Compound 86 ¹H-NMR




Compound 86 ¹³C-NMR




Compound S34 ¹H-NMR



Compound S34 ¹³C-NMR



Compound S35 ¹H-NMR



Compound S35 ¹³C-NMR

